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Chapter One: Introduction and Literature Review 
This review summarizes the current knowledge surrounding nesfatin-1, a multifunctional 
protein hormone, and its potential function in lean, overweight, and diabetic cats. The connection 
between nesfatin-1, glucose homeostasis, and insulin function, as well as the effects of nesfatin-1 
on food intake and weight control will be of particular focus. The pathophysiology and current 
treatment strategies of feline diabetes mellitus will be explored. The current knowledge of central 
and peripheral tissue expression of nesfatin-1 and the effects of nesfatin-1 on glucose 
homeostasis will be reviewed. The implications of how these effects could influence our 
understanding of feline obesity, insulin resistance, and diabetes will be discussed. Finally, the 
knowledge gaps that are present and how our objectives will address these knowledge gaps will 
be discussed. 
 
1.1 Obesity and Diabetes Mellitus in Cats 
Obesity and obesity-related diseases are an increasing problem in domestic cat 
populations, following similar trends with human type 2 diabetes mellitus (T2DM). The 
prevalence of feline diabetes mellitus varies, but is reported to be between 0.25-1%, up from 
0.08% from an initial 1970 study [1]. Approximately 90% of feline diabetes cases are of a 
similar pathophysiological mechanism to T2DM in humans [1], with the major similarity being 
the presence of insulin resistance, though additional pathological changes seen in humans, such 
as atherosclerosis and hypertension, are not commonly seen in cats [2]. As insulin resistance and 
irregular insulin secretion progresses [2,3], persistent hyperglycemia results in a cycle of 
decreased ß-cell function, continued hyperglycemia and further ß-cell dysfunction [4]. Cats with 
diabetes are approximately six times less sensitive to insulin than healthy controls [1], though 
cats are also thought to be able to tolerate insulin resistance and maintain fasting and post-
prandial normoglycemia for years before clinical illness manifests [2]. This tolerance is primarily 
achieved through a reduction in hepatic glucose production [2]. 
Although diabetes is well described in cats, there are still deficiencies related to both the 
diagnosis and management of the condition. Treatment of diabetic cats generally involves the 
administration of exogenous insulin injections and a high protein, low carbohydrate diet, as these 
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diets are associated with reduced post prandial glucose concentrations and insulin secretion [5]. 
However, treatment requires owners to administer these injections along with close glucose 
monitoring at home and/or frequent veterinary visits, requiring significant investments in time, 
money, and effort. This is not always achievable, and it is estimated around 30% of cats are 
euthanized within a year of the initial diagnosis [4]. The ideal clinical outcome is for a diabetic 
cat to enter diabetic remission with treatment, which has been defined as the maintenance of 
normoglycemia without any need for exogenous insulin for at least four weeks [4]. However, 
remission rates are variable. In some studies remission rates reach around 20 to 40% [6], while 
others have seen remission rates of over 80% [7,8]. Such a high remission rate would indicate a 
favourable prognosis; however, studies achieving high rates of remission were conducted in a 
veterinary teaching hospital and are likely not representative of the general owned cat 
population. These remission rates were achieved with rigorous glycemic control, with glucose 
levels being measured up to five times per day [9], something that is not feasible for many 
owners. 
Another issue is that there is currently no reliable marker to help identify feline diabetics 
that have a higher chance of achieving remission [4], or to identify the presence of insulin 
resistance without clinical diabetes i.e., prediabetics [2]. For example, tests that are used in 
humans to demonstrate insulin resistance, such as the intravenous glucose tolerance test, do not 
accurately reflect either glucose homeostasis in lean healthy cats or the presence of insulin 
resistance in obese cats [2]. A reliable assay to measure feline endogenous insulin is also not 
widely available [2], though an assay designed for feline and human insulin has been validated 
for use in cats [10]. Furthermore, endogenous insulin concentrations in cats show high levels of 
intra and inter-individual biological variability [11]. Therefore, a single insulin measurement 
may not be representative of overall insulin secretory capabilities in cats. A marker that could 
detect insulin resistance, especially prior to the onset of diabetes mellitus, would provide benefits 
in both scenarios. If insulin resistance is identified before diabetes occurs, treatment may be less 
intensive. For example, humans with prediabetes are generally managed with non-
pharmacological methods, including weight loss, dietary alterations, and physical activity [12]. 
Identifying this state in cats might avoid the need for exogenous insulin or rigorous glucose 
monitoring. Alternatively, if owners could know before beginning treatment that their cats had a 
high chance of remission, this would provide added motivation to maintain strict glycemic 
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control, as there would be a higher chance of being able to discontinue treatment. Currently, 
factors associated with a higher chance of remission include the achievement of rapid glycemic 
control, administration of glargine insulin twice daily, less severe hyperglycemia at presentation, 
the absences of hypercholesterolemia at diagnosis, and a shorter duration of diabetes before 
diagnosis [4,7]. However, these indicators can be unreliable, and in the case of duration of 
diabetes before diagnosis, difficult to ascertain. Furthermore, the achievement of rapid glycemic 
control is only able to be measured after treatment is started. If a marker existed that predicted if 
a cat was likely to achieve rapid glycemic control before starting treatment, as mentioned 
previously this could provide important additional motivation. Nesfatin-1 has potential as a 
marker to identify these states in cats. 
 
1.2 Nesfatin-1: Initial Discovery, Central Expression, and Effects on Food Intake 
Nesfatin-1 is a recently discovered multifunctional protein hormone, with much of the 
research related to where it is expressed within the brain, the pathways through which its actions 
are exerted, and its effects on the modulation of food intake. Nesfatin-1 was initially described in 
2006 in a study of rats [13]. It is derived from the precursor nucleobindin 2 (NUCB2), and 
processed into three separate fractions, nesfatin-1, nesfatin-2, and nesfatin-3, with the functions 
of nesfatin-2 and 3 currently unknown [13]. Many antibodies used to identify nesfatin-1 cannot 
distinguish between NUCB2 and the cleaved nesfatin-1 protein, so they are often described 
together [14]. Nesfatin-1 was identified in areas of the brain in rats (arcuate nucleus, 
paraventricular nucleus, supraoptic nucleus, lateral hypothalamic area, solitary tract nucleus) that 
are typically associated with the regulation of food intake [13].  
Nesfatin-1 appears to exert its effects though a variety of signalling pathways typically 
associated with food intake, and these pathways also give rise to additional functions of nesfatin-
1. Nesfatin-1 is considered to act through melanocortin signalling in the hypothalamus in rats 
[13]. This pathway involves the processing of pro-opiomelanocortin (POMC) into alpha-
melanocyte stimulating hormone (a-MSH), with POMC expressing neurons located in the 
hypothalamus and brainstem possessing anorexigenic activity [15]. In pigs, this melanocortin 
pathway is thought to regulate appetite, growth and adiposity [16]. In support of this, 
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melanocortin antagonists were found to eliminate the effects of nesfatin-1 on food intake [13]. 
Similarly, blocking corticotropin releasing factor (CRF) pathways removed the inhibitory effects 
of nesfatin-1 [17], suggesting nesfatin-1 may act through both melanocortin and CRF pathways 
to exert its anorexigenic effects. Additional regulation likely occurs through oxytocin, as 
oxytocin antagonists have been found to suppress the effects of both nesfatin-1 and a-MSH when 
administered centrally [18]. 
In addition to its central effects, there is also evidence to suggest that nesfatin-1 acts via a 
combined central and peripheral route to control food intake, potentially involving the Gut-
Hypothalamic-Pituitary axis. Nesfatin-1 associated neurons may be activated by cholecystokinin 
(CCK), a gut peptide that may act as an endocrine messenger [19] and is associated with satiety 
signalling [17]. In an in vitro mouse model, nesfatin-1 was shown to activate neurons isolated 
from vagal afferent ganglia, which are also responsive to CCK [20]. Furthermore, gastric acid 
secretion can be inhibited by central administration of nesfatin-1, via a mechanism that involves 
vagal efferent nerves [21], and nesfatin-1 is released from the synaptic endings of vagal neurons, 
suggesting a role in gastrointestinal secretory and motor activity [22]. Nesfatin-1 expressing 
neurons projecting from the dorsal motor nucleus of the vagus nerve also project to the pancreas 
and the stomach, which suggests this pathway may have an additional function related to central 
glucose and insulin signalling [23]. Lastly, nesfatin-1 is able to cross the blood brain barrier via a 
non-saturable mechanism, with preferential uptake occurring in the hypothalamus [24], which 
further implies the ability of peripheral nesfatin-1 to affect central nesfatin-1 functions, and vice 
versa.  
Given the areas of centrally expressed nesfatin-1, much of the research has focused on 
the effects of centrally administered nesfatin-1 in relation to food intake, satiety, and weight loss. 
Central administration of nesfatin-1 has been found to consistently reduce food intake. Acute 
intracerebroventricular (ICV) administration of purified nesfatin-1 (5 pmol) decreased food 
intake for approximately six hours, and chronic ICV administration (10 days) reduced both food 
intake and body weight gain in rats [13]. Blockage of nesfatin-1 activity then corresponded to an 
increase in food intake [13]. Similar effects were also demonstrated in pigs [16]. This reduction 
in food intake occurred in part due to  reduced gastric emptying and prolonged gastrointestinal 
transit time [17,25]. This reduction in motility is one mechanism through which nesfatin-1 
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induces satiety. This effect is considered to be dose dependant, as higher doses of ICV nesfatin-1 
in mice (3 ug) suppressed food intake for at least 12 hours [26], and ICV administration of a dose 
five times higher than the study by Oh-I (25 pmol/L vs 5 pmol/L) affected food intake for over 
48 hours. This higher dose reduced meal size and meal frequency in the mice [26]. Furthermore, 
fasting reduces NUCB2 mRNA expression in the brain and the stomach [27,28], suggesting that 
NUCB2/nesfatin-1 levels decrease with prolonged fasting, as no satiety signal is required, and 
increases again after re-feeding. 
 
1.3 Nesfatin-1 Expression in Peripheral Tissues 
In addition to characterization of the central effects of NUCB2/nesfatin-1, expression in 
peripheral tissues has also been described, with the distribution reflecting its role in various 
metabolic functions. Nesfatin-1 has been described in the stomach of many different species [28–
31], and the stomach is considered to be the major source of circulating nesfatin-1 [14]. Gastric 
expression of NUCB2/nesfatin-1 mRNA in rats was found to be 10 times higher than in the brain 
[28]. Furthermore, pro-hormone cleavage enzymes are abundant in gastric mucosa [32], which 
could also point towards the stomach being the site of both NUCB2 production and processing 
into nesfatin-1 protein [33]. Nesfatin-1 is also co-expressed with ghrelin within ghrelin 
producing X/A like endocrine cells and stored within separate populations of intra-cytoplasmic 
vesicles [28]. These cells have significant roles in appetite control and gastrointestinal motility, 
two key functions of nesfatin-1. Ghrelin opposes nesfatin-1 by increasing food intake, suggesting 
that these cells play an important role in food regulation, with differential release of nesfatin-1 
and ghrelin depending on the nutritional status of the animal. This further suggests integration 
between gastric nesfatin-1 expression and central control of food intake.  
While the stomach is considered to be the major source of nesfatin-1, several other sites 
that express nesfatin-1 have been identified. Other gastrointestinal tissues that have been shown 
to express NUCB2/nesfatin-1 mRNA or nesfatin-1 protein include the pancreas (in ß-cells co-
localized with insulin), the small and large intestine in dogs and pigs [31,34,35], and the gut of 
fish [36]. Additional sites of nesfatin-1 expression include adipose tissue, cardiomyocytes and 
reproductive tissues [14], and other tissues i.e., liver, adipose tissue, skeletal muscle are affected 
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by nesfatin-1 [37]. This suggests nesfatin-1 has a pleiotropic action depending on the target 
tissue, which will be further discussed below. Species differences in the tissue expression of 
nesfatin-1 likely exist [28,31,35,38], though it can be difficult to determine if these differences 
are solely due to the species studied, or whether analytical differences play a role e.g., 
identifying nesfatin-1 protein with western blot or immunoreactivity. 
 
1.4 Potential Differences in Nesfatin-1 Expression in Cats 
These potential species differences in peripheral NUCB2/nesfatin-1 expression may be of 
particular importance in cats given their different metabolic functions compared to other species 
that are commonly used to study nesfatin-1. While nesfatin-1 has been underexplored in cats, one 
study has looked into feline nesfatin-1 expression in comparison to other species [31]. In this 
study, NUCB2/nesfatin-1 mRNA and protein were identified in the stomach of a cat, a dog and a 
pig [31]. Interestingly, on analysis of the pancreas, it was found that only NUCB2/nesfatin-1 
mRNA was found in the cat pancreas, whereas both mRNA and formed protein were found in 
the ß-cells of the pancreas in dogs and pigs [31]. It was hypothesized that this difference may be 
due to differences in digestive physiology and glucose metabolism between carnivorous and 
omnivorous species. It is also hypothesized that this pancreatic nesfatin-1 may act locally on ß-
cells in the pancreas to exert effects on insulin regulation [19]. If cats lack this ability, it could 
represent a risk factor for the development of insulin resistance or altered insulin function in cats. 
An alternative explanation is that these samples were collected from lean healthy cats, and the 
presence of nesfatin-1 mRNA could indicate a functional reserve in the pancreas of cats. If this 
were the case, then nesfatin-1 protein in the pancreas may only be produced in states where there 
is impaired insulin function e.g., impaired glucose tolerance or diabetes mellitus, and a 
difference would be seen in expression among lean healthy cats, overweight or obese cats with 
insulin resistance, and diabetic cats. However, given that only a single cat was evaluated in this 
study it is difficult to draw any definitive conclusions, and it is possible that the pattern seen in 
this one cat is not representative of the species as a whole. 
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1.5 Effects of Peripheral Nesfatin-1 on Food Intake 
Peripherally produced nesfatin-1 may also affect food intake and satiety similar to central 
nesfatin-1, though the evidence is less conclusive. Several studies have investigated the effects of 
peripherally administered nesfatin-1 on food intake and energy homeostasis, and results are 
variable, depending on the dose of nesfatin-1 and duration of administration. For example, 
intraperitoneal administration of 200 pmol of nesfatin-1 in rats did not affect dark phase food 
intake [17], and a single high dose (7000 pmol) of nesfatin-1 administered IP in mice did not 
alter meal size or meal frequency. Conversely, a single IP injection of nesfatin-1 (250 pmol/g) in 
both lean and obese mice resulted in the acute reduction of dark phase food intake [15]. The 
reason for this discrepancy in the effects of IP nesfatin-1 on food intake is not immediately clear. 
Peripheral nesfatin-1 shows greater effects when given over a longer period of time. 
Administration of 5000 pmol/kg/day nesfatin-1 via osmotic pump over 24 hours reduced food 
intake in the dark phase in rats [27] and this trend was also seen when nesfatin-1 was 
administered over seven days. Interestingly, physical activity also increased yet body weight was 
unaffected in this study [27]. Similar results have been seen in fish [39]. Another study in mice 
found no effect with long term nesfatin-1 administration; however, the dose administered (60 
pmol/day) was significantly lower (Prinz Stengel 2016). The main factors in peripheral nesfatin-
1 affecting food intake appear to be the dose administered and especially the duration of 
administration. The half-life of nesfatin-1 in blood is less than 10 minutes in mice [40] and 
nesfatin-1 is likely excreted through the renal system [24]. Therefore, longer term administration 
and higher doses of nesfatin-1 are thought to be required to impact food intake significantly, as 
single injections are cleared too quickly to have a lasting effect. In most animals, it appears that 
constant infusions or persistently increased circulating levels of nesfatin-1 are likely required for 
it to affect target tissues, both in relation to food intake and other functions i.e., glucose 
metabolism. This is in addition to any local or autocrine effects nesfatin-1 may have. 
Importantly, these effects are likely independent of leptin [15], implying nesfatin-1 maintains its 
functionality in cases of obesity and leptin resistance. 
While peripheral nesfatin-1 does appear to influence food intake, it is debatable whether 
these changes can be observed by measuring blood nesfatin-1 concentrations. A rat study 
previously mentioned discovered that rats fasted for 24 hours had significantly decreased plasma 
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nesfatin-1 concentrations, and levels returned to baseline after re-feeding [17], suggesting food 
intake can affect peripheral nesfatin-1. Conversely, in a study of dogs fed a variety of diets, 
gastric mRNA expression of nesfatin-1 was increased with high protein and high fibre diets 
while plasma nesfatin-1 concentrations were unchanged [30]. This may again point to nesfatin-1 
acting directly through vagal pathways without involving circulating nesfatin-1, and a direct 
connection between gastric and central nesfatin-1. However, the possible connection between 
fasting and circulating nesfatin-1 suggests that the time of blood sampling e.g., fasted versus post 
prandial may be an important variable to consider. Furthermore, the potential effects of dietary 
manipulation on nesfatin-1 expression may warrant further investigation, especially as high 
protein diets - diets commonly provided to diabetic cats and for the purposes of weight loss - 
appear to exert significant effects. It remains to be seen whether these diets could induce changes 
in peripheral nesfatin-1 in cats and whether the different nutritional requirements of cats 
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Route of  
Administration 












Decreased food intake, weight loss [13,26] 
Decreased gastric emptying, prolonged GI transit time [17,25] 
Anxiety like behaviour (high doses) [41] 
Increased ACTH and corticosterone concentrations [29] 
















Decreased food intake [15,27], note other studies did not see reduced food 
intake with IP nesfatin-1 [17,38] 
Decreased plasma free fatty acid levels [43] 
Decreased plasma cholesterol [44] 
Decreased blood glucose (in hyperglycemic mice only) [45] 
Increased serum insulin levels and insulin mRNA expression, increased 
insulin sensitivity [37] 
Table 1.1: Effects of nesfatin-1 depending on the route of administration in experimental 
laboratory animal models 
 
1.6 Correlations Between Nesfatin-1 and Adiposity 
Similar to its anorexigenic effects, nesfatin-1 may have implications in obesity and 
adiposity, indicating a role in overall body metabolism. However, it remains to be seen whether 
these findings are applicable to cats. In diabetic mice, intravenous (IV) nesfatin-1 administration 
over six days improved utilization of fatty acids, and reduced plasma free fatty acid levels [43], 
indicating a link between nesfatin-1 and lipid metabolism. Chronic administration was also 
found to reduce plasma cholesterol [44]. A study in humans found plasma nesfatin-1 was 
positively correlated with Body Mass Index (BMI) and levels did not appear to plateau as BMI 
 - 17 - 
increased [46]. Similarly, T2DM patients undergoing bariatric surgery had decreased nesfatin-1 
levels that were correlated with decreased BMI [29]. In this context, nesfatin-1 appears to display 
similar functions to adiponectin. Adiponectin is an adipokine implicated in obesity in cats and 
dogs, with functions similar to some of those seen with nesfatin-1 i.e., increased insulin 
sensitivity and peripheral glucose uptake [47]. In humans, adiponectin improves insulin 
sensitivity via insulin signalling in skeletal muscle and reduced hepatic gluconeogenesis [48]. 
Given the similar effects of adiponectin and nesfatin-1, altered nesfatin-1 expression is likely 
implicated (either as a cause or a response to) in the development of obesity and lipid disorders, 
in addition to its effects on glucose metabolism. These similarities also point towards nesfatin-1 
having potential as a marker or even as a treatment of obesity and obesity related disorders, 
especially given its leptin-independent mode of action.  
The role of adiponectin in diabetes and obesity in humans and cats has been investigated. 
Interestingly, adiponectin levels were decreased in obese cats compared with lean cats and were 
lower still in diabetic cats [49]. This pattern of expression was also documented in humans. 
Plasma adiponectin concentrations in humans generally decrease as body weight increases, and 
adiponectin levels also appear to decrease as the degree of insulin resistance increases [50].  
Conversely, despite their similar functions, the opposite association has been demonstrated with 
nesfatin-1 in humans, where plasma nesfatin-1 concentrations increase as body weight and 
insulin resistance increase. The effects of nesfatin-1 on reducing cholesterol may also provide 
additional use in the diagnosis and management of feline diabetes, as hypercholesterolemia has 
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Plasma Concentrations in 
Diabetic Humans 
Nesfatin-1 Improved insulin sensitivity in insulin 
sensitive cells [37] 
Increased insulin secretion from pancreatic 
ß-cells [51] 
Reduced hepatic gluconeogenesis and 
improved peripheral glucose uptake 
(central administration) [42] 
Increased [29,46] Increased* [52–54] 
 
*Only increased in newly 
diagnosed or untreated 
diabetics 
Adiponectin Improved insulin sensitivity in skeletal 
muscle [48] 
Reduced hepatic gluconeogenesis [48] 
Decreased (Weyer et 
al., 2001) 
Decreased [49,50] 
Table 1.2: Comparisons between the functions of nesfatin-1 and adiponectin in relation to 
glucose homeostasis, and differences in plasma nesfatin-1 and adiponectin concentrations in 
obese and diabetic humans in comparison to lean healthy controls 
 
1.7 Other Clinical Factors That May Influence Nesfatin-1 Expression 
Nesfatin-1 likely affects a wide variety of organ systems, and while these effects are not 
the major focus of this study, they must be considered, especially in the selection of study 
subjects and identification of other variables that may influence study results. Nesfatin-1 levels 
were found to be increased in hypertensive human patients who were confirmed to be free of 
diabetes or impaired glucose tolerance [55]. Conversely, circulating nesfatin-1 levels in humans 
are significantly decreased with other forms of cardiovascular disease, namely carotid artery 
stenosis [56] and acute myocardial infarction [57]. Nesfatin-1 is also considered to have 
cardioprotective effects in mammals [58]. While these potential effects of nesfatin-1 should not 
impact diabetic cats directly, as hypertension is not a common symptom associated with feline 
diabetes [2], cats that have concurrent cardiac disease or other diseases affecting blood pressure 
e.g., advanced renal disease and hyperthyroidism, may have unpredictably altered nesfatin-1 
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concentrations. Additionally, central nesfatin-1 has been found to induce anxiety-like behaviours 
in rats [41], although higher doses are required to induce anxiety behaviours than are needed to 
alter food intake [59]. Studies in humans have also shown elevated nesfatin-1 in patients with 
depression, with levels positively correlated with the severity of depression [60]. However, 
nesfatin-1 also varies with both the type of mental illness present and sex of the study subjects 
[19]. These relationships may be related to the pathways through which nesfatin-1 can act, as 
ICV nesfatin-1 can increase plasma Adrenocorticotropic Hormone (ACTH) and corticosterone 
concentrations in rats, likely through interactions with CRF, the hypothalamic-pituitary-axis and 
the sympathetic nervous system [29,54]. This interaction between nesfatin-1 and the 
hypothalamic pituitary axis is unsurprising as, generally, food intake, stress, and anxiety are 
closely related [14]. Again, while this interaction should not specifically affect diabetic patients, 
if they have any diagnosed or clinically suspected anxiety or behavioural disorders, nesfatin-1 
expression may be altered. 
 
1.8 Correlations Between Nesfatin-1 and Glucose Homeostasis 
One of the important functions of nesfatin-1 is its insulinotropic effects on glucose 
homeostasis. Previous research has found that nesfatin-1 can directly stimulate insulin secretion 
from ß-cells, primarily in hyperglycemic states. For example, in vitro studies on isolated mouse 
pancreatic islet cells found that nesfatin-1 increased insulin secretion in a dose- dependent 
manner, and this effect was significantly greater in cells that were exposed to high glucose 
concentrations [51]. Furthermore, higher nesfatin-1 concentrations than what are typically seen 
in lean, healthy subjects are required to stimulate insulin secretion from pancreatic islets in mice 
[19], and IV injections of nesfatin-1 significantly decreased blood glucose in hyperglycemic 
mice only [45]. In this mouse study, blood levels of insulin were largely unchanged in the short 
term [45]. However, nesfatin-1 administered to a type 1 diabetes mellitus mouse model did not 
affect blood glucose levels, indicating insulin is required for nesfatin-1 to function [45]. Other 
studies did demonstrate increased serum insulin levels after chronic sub-cutaneous nesfatin-1 
administration, with in vitro models showing increased insulin mRNA expression [37]. Together, 
these findings imply that nesfatin-1 predominantly influences glucose homeostasis when glucose 
homeostasis is impaired. Nesfatin-1 may act by both increasing insulin sensitivity and insulin 
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secretion, supporting the idea of nesfatin-1 acting as a mechanism to try and maintain insulin 
function when insulin resistance is present.  
Aside from nesfatin-1’s direct effects on the pancreas, it also has additional effects on 
peripheral tissues in relation to glucose homeostasis. In both in vitro and in vivo models, the 
effects of insulin and nesfatin-1 on AKT phosphorylation, a marker of peripheral insulin 
signalling in islet cells, liver, skeletal muscle and adipose tissue, were studied [37]. 
Administration of peripheral nesfatin-1 increased AKT phosphorylation in all tissues, in both 
control mice and mice fed a high fat diets [37]. This increased phosphorylation suggests that 
nesfatin-1 improves insulin sensitivity in peripheral tissues and pancreatic islet cells, and that this 
may occur in both lean and obese animals. The administration of nesfatin-1 also increased the 
expression of glucose transporter 4 in muscle and adipose tissue. Furthermore, expression of 
NUCB2/nesfatin-1 mRNA and protein in muscle and adipose tissue was increased in human 
T2DM patients compared with healthy controls [53]. These findings indicate a role for nesfatin-1 
in compensating for altered insulin function by improving peripheral uptake of glucose.  
There is also evidence that central nesfatin-1 may have an influence on overall glucose 
homeostasis, and this finding may be of particular relevance in cats. In one study, an ICV dose of 
nesfatin-1 was administered in rats with insulin resistance, and it was found that this dose 
significantly increased the ability of insulin to suppress hepatic gluconeogenesis and enhance 
peripheral glucose uptake [61]. This implies a connection between central and peripheral 
nesfatin-1 on glucose homeostasis, either through a direct neural pathway or via the blood brain 
barrier. One of the pathological mechanisms in the development of impaired glucose tolerance in 
humans is the reduced ability of insulin to suppress hepatic gluconeogenesis [12]. This 
mechanism may be of particular importance in cats, as cats are able to tolerate insulin resistance 
predominantly through their ability to maintain hepatic insulin sensitivity [2]. If this ability is in 
part mediated by nesfatin-1, then insulin resistance could potentially be identified by measuring 













Figure 1.1: Suggested mechanisms by which nesfatin-1 may act to maintain insulin sensitivity 
and counteract persistent hyperglycemia 
 
1.9 Nesfatin-1 and Diabetes Mellitus in Humans, and the Potential Utility of 
Nesfatin-1 in Feline Diabetics  
Given these effects on glucose homeostasis, nesfatin-1 has been investigated in relation 
to disorders of glycemic control. Nesfatin-1 levels in human T2DM were inconsistent. Some 
studies have shown that circulating nesfatin-1 concentrations are lower in T2DM patients 
compared with healthy controls [33,62], whereas other studies showed the opposite association 
[52–54]. A meta-analysis [63] revealed that the main factor in these disparate results was 
whether patients had received diabetic treatment, with the time since diagnosis also being a 
partial factor. Patients with newly diagnosed untreated T2DM had elevated nesfatin-1 levels 
compared with controls. However, diabetics that were receiving treatment had lower nesfatin-1 
concentrations compared with healthy controls. This decrease in nesfatin-1 may be due to either 
the resumption of glycemic control and the reversal of glucose toxicity, or the continued loss or 
dysfunction of pancreatic ß-cells, resulting in decreased insulin secretion and consequently 
reduced stimulus for nesfatin-1. Nesfatin-1 has also been found to be increased in patients with 
impaired glucose tolerance (IGT) [52,54], which is analogous to a prediabetic state. In contrast, 
another study found that nesfatin-1 was decreased in IGT patients [62], though it is unclear if 
these patients were receiving any other treatments e.g., oral anti-hyperglycemics. These 
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inconsistent findings make it difficult to predict nesfatin-1 levels in patients that achieve diabetic 
remission i.e., the resumption of glycemic control without the requirement of exogenous insulin, 
as these patients undergo treatment, but then at some point are no longer considered diabetic. In 
cats at least, it is suggested that diabetics that achieve remission still do not have normal ß-cell 
function and clinically should be considered ‘prediabetic’ [9]. This residual ß-cell dysfunction 
suggests that as remission occurs, nesfatin-1 may return to healthy control levels as glycemic 
control resumes or may stay slightly elevated due to the residual impaired glucose tolerance. In 
summary, it appears that circulating nesfatin-1 concentrations increases with impaired glucose 
tolerance and insulin resistance, culminating with T2DM. Then, as T2DM patients receive 
treatment, and possibly as treatment continues over time, nesfatin-1 levels decrease. This pattern 
could be related to continued glucose toxicity and ß-cell necrosis over time, which could 
subsequently lead to reduced nesfatin-1 secretion. 
Overall, the changes in nesfatin-1 seen in disorders of glycemic control, and the 
similarities of feline diabetes mellitus and human T2DM demonstrate the potential utility of 
circulating nesfatin-1 in feline patients. Specifically, as insulin resistance occurs, nesfatin-1 
concentrations may increase as a compensatory mechanism to help maintain insulin sensitivity 
and normoglycemia. If so, this mechanism indicates that nesfatin-1 could be used as a marker of 
insulin resistance, both when clinical diabetes mellitus is present, but also to identify a 
prediabetic state. Identifying insulin resistance before clinical diabetes would be the ideal 
scenario as treatment is less arduous for the owner. It may also be of particular interest in cats 
given their compensatory abilities and how long they tolerate insulin resistance [2]. This 
prolonged time frame would theoretically give a larger clinical window for insulin resistance to 
be identified and managed. As clinical diabetes develops, nesfatin-1 may have additional use in 
monitoring the response to therapy, or possibly helping to predict the chances of remission being 
achieved. Given the findings of nesfatin-1 in relation to long term human diabetics [33,62], the 
use of nesfatin-1 in the long-term monitoring of diabetes may be of less benefit, due to the 
continued ß-cell dysfunction and/or necrosis. Given the effects of nesfatin-1 in relation to its 
effects on lipid metabolism, cholesterol, food intake, and glycemic control, nesfatin-1 may even 
have use as a therapeutic treatment in the management of obesity, diabetes, and other metabolic 
disorders. 
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1.10 Summary and Research Objectives 
Despite the connections between nesfatin-1, diabetes, obesity, adiposity, and food intake, 
and the similarities between feline diabetes and human T2DM, nesfatin-1 has been 
underexplored in cats. At this time there is only one study that has investigated nesfatin-1 in cats 
[31]; This study evaluated nesfatin-1 expression in the stomach and pancreas of a single cat, and 
the plasma of eight healthy cats. While it is useful to have a small amount of baseline data, as 
well as the knowledge that nesfatin-1 is detectable in feline blood [31], there is room to expand 
our understanding. No research has been conducted into nesfatin-1 expression in overweight or 
diabetic cats, and this knowledge gap is what this thesis aims to evaluate. Chapter one will 
investigate tissue expression of nesfatin-1 mRNA in gastro-intestinal and peripheral tissue, and 
comparisons made between lean, overweight, and diabetic cats. Chapter two will then evaluate 
and characterize plasma nesfatin-1 concentrations between these groups, as well as investigating 
how treatment of diabetic patients impacts plasma nesfatin-1 concentrations. The potential 
changes in nesfatin-1 expression among groups will provide further information as to whether 
nesfatin-1 changes with metabolic disorders in cats in similar ways to other species, namely 
humans and laboratory animals.  
Given the similarities, in particular the development of insulin resistance, between feline 
diabetes and human T2DM, we hypothesize that nesfatin-1 will play a role in the compensation 
for insulin resistance and altered glucose homeostasis in cats. However, the specialized 
metabolic and nutritional physiology found in cats adds a potential unpredictable variable. For 
plasma nesfatin-1 concentrations, we hypothesize that newly diagnosed diabetic cats will have 
significantly higher nesfatin-1 levels compared with lean and overweight healthy cats, and that 
levels will decrease as cats undergo treatment and glycemic control improves. Conversely, an 
additional effect may be seen in patients that undergo remission during the study. These patients 
may have lower nesfatin-1 at presentation compared with diabetic cats that do not achieve 
remission, which would reflect comparatively better glycemic control at the start of treatment. 
Overweight cats may have higher nesfatin-1 levels than lean healthy controls, particularly if 
these overweight cats have some degree of insulin resistance. We also hypothesize that we will 
see similar changes in nesfatin-1 tissue mRNA expression among lean, overweight, and diabetic 
cats. Expression may be higher in diabetic and overweight cats compared with lean healthy cats, 
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owing to increased synthesis of nesfatin-1 as a compensatory mechanism for the presence of 
insulin resistance. 
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Chapter Two: Evaluation of NUCB2/ Nesfatin-1 mRNA Tissue Expression in Lean, 
Overweight, and Diabetic Cats 
 
2.1 Abstract 
Background: Rates of obesity and diabetes mellitus are increasing in domestic cats. 
Nesfatin-1 is a protein hormone implicated in controlling food intake and maintaining glycemic 
control. The role of nesfatin-1 in the pathophysiology of obesity and diabetes mellitus in cats has 
not been evaluated. This study aimed to characterize NUCB2/nesfatin-1 mRNA expression in 
feline gastric, pancreatic, abdominal adipose, and skeletal muscle tissue, and to evaluate how 
tissue nesfatin-1 expression differs between lean, overweight, and diabetic cats.  
Methods: Case control study. Four lean, three obese, and five diabetic cats were 
sampled. RNA was extracted from pancreas, stomach, abdominal fat, and skeletal muscle, and a 
one-step RT-PCR was performed. Relative NUCB2/nesfatin-1 expression was assessed by the 
comparative 2-Ct method. 
Results: NUCB2/nesfatin-1 mRNA expression was highest in the pancreas and there was 
a wide variance in tissue expression in all cats. Expression tended to be marginally decreased in 
pancreatic tissue of overweight cats in comparison to lean cats. NUCB2/nesfatin-1 expression in 
the gastric and pancreatic tissue of diabetic cats showed a biphasic pattern. Two diabetic cats had 
similar expression patterns to lean cats, while three diabetic cats had decreased expression 
compared to lean cats. This biphasic expression was unrelated to the body condition or treatment 
status of these diabetic cats. No patterns of expression were identified in adipose and muscle 
tissue. 
Conclusions: The pancreas had the highest levels of NUCB2/nesfatin-1 mRNA 
expression in cats. Changes in expression in diabetic cats were most pronounced in the stomach 
and pancreas. The biphasic pattern of expression in diabetic cats may reflect differences in 
pancreatic islet health and function in these cats. The clinicopathological implications of these 
changes need to be investigated further. Future studies may involve assessing changes in 
nesfatin-1 mRNA expression in conjunction with changes in nesfatin-1 tissue protein expression 
and circulating nesfatin-1 concentrations.  
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2.2 Introduction 
The prevalence of obesity and obesity-related diabetes mellitus is increasing in both 
humans and cats [1]. Feline diabetes shares many clinicopathological features with human type 2 
diabetes mellitus (T2DM), such as middle age, obesity, and peripheral insulin resistance [2,47]. 
It is considered that approximately 90% of feline diabetes cases share similar pathophysiological 
mechanisms to T2DM in humans, namely the development of insulin resistance [1]. 
Furthermore, cats with diabetes are approximately six times less sensitive to insulin than healthy 
controls [1], and cats are able to tolerate insulin resistance for years before clinical illness 
manifests [2]. 
Nesfatin-1 is a highly conserved, multifunctional protein hormone derived from the 
nucleobindin 2 (NUCB2) gene. It is expressed within multiple regions in the brain in rats, 
particularly in areas involved in feeding regulation and appetite control [13,17]. Nesfatin-1 has 
been found to exert a wide variety of functions in various species, including control of glucose 
homeostasis, food intake and adiposity. Intracerebroventricular injection of nesfatin-1 in rats has 
been shown to reduce gastric emptying [25], food intake, and weight gain [13]. Chronic 
peripheral administration of nesfatin-1 may also reduce food intake and modulate energy 
homeostasis in rats [27]. Furthermore, the stomach is considered the main source of circulating 
nesfatin-1 [14], suggesting a link between dietary composition, weight loss and peripheral 
nesfatin-1 levels. Intravenous nesfatin-1 administration has been found to increase the expression 
of enzymes promoting fatty acid oxidation in skeletal muscle [43] and decrease fatty acid 
synthesis in the liver [38]. In the mouse, nesfatin-1 has insulinotropic effects. It can directly 
stimulate insulin secretion from pancreatic islet cells in vitro, and augment insulin secretion and 
glucagon suppression in vivo [51]. Furthermore, higher nesfatin-1 concentrations than what are 
seen in lean healthy subjects are required to stimulate insulin secretion [19], and IV nesfatin-1 
only significantly decreased blood glucose levels in mice that were hyperglycemic [45]. 
Intravenous administration of nesfatin-1 also helps to normalise serum fatty acid levels and body 
weight in diabetic mice [14]. Nesfatin-1 has also been shown to increase uptake of glucose in 
peripheral tissues and improve insulin sensitivity [38]. These effects may reflect a potential 
diagnostic or therapeutic role of nesfatin-1 in patients with obesity or diabetes mellitus. 
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Despite the increasing prevalence of obesity and diabetes in cats [1] and the functions of 
nesfatin-1 in relation to these issues, nesfatin-1 is relatively under explored in this species. In 
domestic veterinary species, nesfatin-1 expression has been described in the stomach and 
pancreas of a single dog, pig, and a cat [31], but further research investigating nesfatin-1 
expression in cats is lacking. The objective of this study was to further understand the role of 
nesfatin-1 in the pathophysiology of obesity and diabetes mellitus in cats by evaluating 
differences in tissue expression of NUCB2/nesfatin-1 mRNA between lean, overweight, and 
diabetic cats. This research will expand the current knowledge of gastrointestinal nesfatin-1 
expression in cats and its potential relationship with glucose metabolism and the development of 
diabetes mellitus. 
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2.3 Materials and Methods 
2.3.1 Study Design  
A case-control study was performed on lean, overweight, and diabetic cats. Cats of any 
age were eligible for enrolment. Lean cats were required to have a body condition score of 4 or 
5/9, and overweight cats a body condition score of greater than 6/9. Diabetic cats were eligible to 
be recruited regardless of body condition score or treatment status. Cats were excluded from the 
study if there was any laboratory evidence of severe renal disease (IRIS stage three or four) or 
hyperthyroidism on a recent biochemistry panel, or from a biochemistry panel run at the time of 
euthanasia. Cats were also excluded if there was previous clinical evidence of heart disease, or 
evidence of disseminated or pancreatic neoplasia during sampling. Tissues from four lean cats 
were donated by a collaborator at the University of Calgary Faculty of Veterinary Medicine 
(UCVM). Tissues from overweight and diabetic cats were collected for this study and for a 
separate study investigating expression of other gastrointestinal hormones from cats presenting 
to the Western College of Veterinary Medicine (WCVM) or the UCVM for euthanasia. 
Experimental protocols were approved by the University of Saskatchewan Animal Research 
Ethics Board (AUP 20170106) and the University of Calgary Animal Care and Use Committee 
(AC20-0023). All protocols were conducted in compliance with each university’s ethical 
guidelines for animal research. No cats were euthanized solely for the purpose of this or the other 
study, but at the request of owners for other health related issues. 
 
2.3.2 Demographics 
Four lean cats, three overweight cats, and five diabetic cats were recruited overall. Of the 
five diabetic cats that were recruited, two were newly diagnosed i.e., they had not received prior 
insulin therapy, one cat had received insulin for three weeks before euthanasia, and two cats had 
received insulin therapy for approximately two months before being euthanized due to severe 
diabetic ketoacidosis (see supplemental table 2.1). One diabetic cat tested Feline Leukemia Virus 
(FeLV) positive on an FeLV blood antigen test (SNAP FIV/FeLV Combo; IDEXX, Canada). 
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2.3.3 Sample Collection 
For all cats, euthanasia was performed with IV pentobarbital and tissue collection was 
performed within 30 minutes following euthanasia. Samples of the gastric body, right limb of the 
pancreas, abdominal skeletal muscle, and abdominal adipose tissue were procured, immediately 
snap frozen in liquid nitrogen, and stored at -80C until RNA extraction. Two of the lean cats did 
not have abdominal fat available to sample, and one did not have any available pancreatic tissue 
(all pancreatic tissue had been used in a prior study). 
 
2.3.4 RNA Extraction 
RNA extraction was performed using different methods for pancreatic and stomach tissue 
compared with adipose and muscle tissue, given the nature of the tissues and comparative RNA 
yields. For pancreas and stomach, tissue was homogenized using RINO RNA lysis tubes 
(catalogue number NAVYR1-RNA; Froggabio, Canada) in 300 uL of buffer RLT as part of the 
RNeasy mini (catalogue number 74104; Qiagen, Canada) RNA extraction kit. The remainder of 
the RNA extraction was performed according to manufacturers’ instructions. For muscle and fat 
tissue, A TRIzol RNA purification kit (catalogue number 12183555, ThermoFisher, Canada) was 
used given the need for stronger cell lysis capability in order to maximise RNA yield. Tissues 
were homogenized with RINO RNA lysis tubes in 600 uL of Trizol, and RNA extraction was 
then performed using the kit according to manufacturers’ instructions. 
For all samples, RNA purity and concentration were evaluated by spectrophotometry 
(Nanodrop, ThermoFisher, Canada) using 260 nm/280 nm optical density (OD) ratios. RNA 
integrity was also evaluated by assessing 18S and 28S Ribosomal RNA bands on agarose gel 
electrophoresis. A portion of the sample was diluted to a concentration of 50 ng/uL, and genomic 
DNA was removed by DNase digestion (Invitrogen DNA removal kit, catalogue number 
AM1906; Fisher Scientific, Canada). The newly diluted sample was again evaluated with OD 
260 nm/280 nm ratios using Nanodrop spectrophotometry to ensure RNA quality after DNA 
digestion. RNA was stored at -80C until analysis. 
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2.3.5 RT-PCR Protocol 
All samples were run in triplicate with a one-step Real Time PCR kit (Quantifast SYBR 
Green RT-PCR, catalogue number 204154; Qiagen, Canada) according to manufacturer’s 
instructions. Briefly, a 25 uL reaction mix was made with 12.5 uL of master mix, 6.25 uL of 
RNase free water, 2 uL of each forward and reverse primer, 2 uL of sample RNA, and 0.25 uL of 
Reverse Transcriptase mix. A negative reverse template control was performed with each sample 
(0.25 uL of Reverse Transcriptase mix was replaced with an additional 0.25 uL of RNase free 
water), along with a non-template control (2 uL of template replaced with 2 uL of RNase free 
water). Real time cycling conditions were set with an initial reverse transcription of 10 minutes 
at 50C, followed by an activation step of 5 minutes at 95C. A two-step cycling method was 
then performed, with 35 cycles of denaturation (10 seconds at 95C) followed by combined 
annealing and extension (30 seconds at 60C). Melt curve analysis was performed to ensure 
specificity of the amplified product, and agarose gel electrophoresis was also performed to 
confirm the targeted amplicon size. The primers to evaluate NUCB2/nesfatin-1 gene expression 
and one reference gene, ß-actin, were validated in a previous study [31]. A second reference 
gene, Ribosomal Protein S7 (RPS7), was selected based on a previous study demonstrating its 
stability in feline tissues in comparison to other reference genes [64] (see supplemental table 2.2 
for primer sequences). 
 
2.3.6 Statistical Analysis 
Relative tissue expression was assessed using the comparative 2-Ct method [65]. 
Briefly, Ct values were obtained for the three amplified gene products, NUCB2/nesfatin-1, RPS7 
and ß-actin. For each tissue, the two reference genes (RPS7 and ß-actin) were averaged, and this 
combined figure was used to normalize NUCB2 expression. For comparison of NUCB2 
expression between the different tissue types, the NUCB2 Ct values in the stomach of all lean, 
overweight, and diabetic cats were averaged. Ct values from the remaining tissues were then 
compared to these averaged stomach values for each group. Normal distribution of these Ct 
values was assessed by a Shapiro-Wilk Test. Differences between NUCB2 expression in the 
stomach, pancreas, skeletal muscle, and abdominal adipose were assessed by a Kruskal-Wallis 
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ANOVA, followed by a Dunn’s test with Bonferroni correction. Statistical significance was set 
at P <0.05. For comparison of tissue expression between lean, overweight, and diabetic cats, the 
NUCB2 Ct values in the stomach, pancreas, abdominal adipose tissue, and skeletal muscle 
were calculated, and expression from individual tissues were compared to the same averaged 
stomach value as per previous. No further statistical analysis was performed on these values due 
to the small sample sizes of each individual group. All graphs were created with GraphPad Prism 
8® (GraphPad Software, CA). 
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2.4 Results 
2.4.1 Relative NUCB2/Nesfatin-1 mRNA Expression Between Tissue Types 
In all cats, pancreatic mRNA expression of NUCB2/nesfatin-1 was significantly higher 
than expression in gastric (P <0.01), skeletal muscle (P <0.01), and abdominal adipose (P = 0.01) 
tissue (Figure 2.1). Expression in the other three tissues was similar, with relative mRNA 
expression slightly lower in skeletal muscle (P = 0.6), and slightly higher in abdominal adipose 
tissue (P = 0.1) in comparison to gastric expression, though these differences were not 
statistically significant. However, these differences in expression were small especially given the 
moderate to marked increase in pancreatic mRNA expression. The variance in pancreatic 
expression was also the most extreme, with a greater than 10-fold difference in expression 
amongst the diabetic cats (low value 11.08, high value 147.03). The variances in expression 
between gastric (0.43 – 2.22), skeletal muscle (0.32 – 1.8), and abdominal adipose tissue (0.62 – 
3.39) were much smaller and showed similar dispersion. No overt pattern of expression was 



























2.4.2 Relative NUCB2/Nesfatin-1 mRNA Expression Between Lean, Overweight, 
and Diabetic Cats 
Expression of NUCB2/nesfatin-1 mRNA in gastric tissue, pancreatic tissue, skeletal 
muscle, and abdominal fat are presented in figures 1.2-1.5. Overall, mRNA expression appeared 
decreased in the overweight and diabetic groups in comparison to lean cats, particularly in the 
gastric and pancreatic tissue, though these differences were not statistically significant. However, 
there is overlap in expression between each of the groups in all the tissues studied. Significant 
individual variation also exists between cats in all three groups. Two diabetic cats (one untreated 
and one treated for two to three months) had high levels of NUCB2/nesfatin-1 mRNA expression 
in their stomach and pancreas, similar to levels seen in lean cats. In contrast, the remaining three 
diabetic cats (one untreated, one treated for three weeks, and one treated for two months) had 
much lower NUCB2/nesfatin-1 expression. In this way, the diabetic cats appear to show a 
Figure 2.1: NUCB2/nesfatin-1 mRNA expression of gastric (n = 12), pancreatic (n = 11), skeletal muscle (n = 
12), and abdominal fat (n = 10) tissue of all lean, overweight, and diabetic cats collected at the Western College 
of Veterinary Medicine and the University of Calgary Faculty of Veterinary Medicine, relative to the average 
NUCB2/nesfatin-1 expression of gastric tissue in all cats (n = 12), Kruskal-Wallis ANOVA 
P < 0.01 P < 0.01 P = 0.01 
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biphasic pattern of expression in pancreatic and gastric tissue. All three overweight cats had 
lower pancreatic NUCB2/nesfatin-1 expression compared with the lean cats. One overweight cat 
had particularly low expression, though this cat did not have concurrently low gastric expression. 



















Figure 2.2: NUCB2/nesfatin-1 mRNA expression of gastric tissue in individual lean (n = 4), overweight 
(n = 3), and diabetic cats (n = 5) collected at the Western College of Veterinary Medicine and the 
University of Calgary Faculty of Veterinary Medicine, relative to the average NUCB2/nesfatin-1 
expression of gastric tissue in all cats (n = 12) 
Gastric Nesfatin-1 Expression 






















Pancreatic Nesfatin-1 Expression 
Skeletal Muscle Nesfatin-1 Expression 
Figure 2.3: NUCB2/nesfatin-1 mRNA expression of pancreatic tissue in individual lean (n = 3), 
overweight (n = 3), and diabetic cats (n = 5) collected at the Western College of Veterinary Medicine and 
the University of Calgary Faculty of Veterinary Medicine, relative to the average NUCB2/nesfatin-1 
expression of gastric tissue in all cats (n = 12) 
 
Figure 2.4: NUCB2/nesfatin-1 mRNA expression of skeletal muscle tissue in individual lean (n = 4), 
overweight (n = 3), and diabetic cats (n = 5) collected at the Western College of Veterinary Medicine and 
the University of Calgary Faculty of Veterinary Medicine, relative to the average NUCB2/nesfatin-1 
expression of gastric tissue in all cats (n = 12) 
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Abdominal Adipose Nesfatin-1 Expression 
Figure 2.5: NUCB2/nesfatin-1 mRNA expression of abdominal adipose tissue in individual lean (n = 2), 
overweight (n = 3), and diabetic cats (n = 5) collected at the Western College of Veterinary Medicine and 
the University of Calgary Faculty of Veterinary Medicine, relative to the average NUCB2/nesfatin-1 
expression of gastric tissue in all cats (n = 12) 
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2.5 Discussion 
 
The results of this study definitively demonstrate that NUCB2/nesfatin-1 mRNA is 
expressed in feline stomach, pancreas, skeletal muscle, and abdominal adipose tissue. mRNA 
expression is tissue dependent, with the highest expression occurring in the pancreas. This study 
also revealed that NUCB2/nesfatin-1 may be differentially expressed in tissues from lean, 
overweight, and diabetic cats, although significant overlap exists between the study groups. 
Overall, tissue expression was marginally lower in overweight cats compared with lean cats, 
whereas diabetic cats displayed a biphasic expression pattern in gastric and pancreatic tissue. 
 
2.5.1 NUCB2/Nesfatin-1 mRNA Expression Between Tissues 
In all cats, NUCB2/nesfatin-1 mRNA expression was significantly higher in pancreatic 
tissue compared to gastric, skeletal muscle, and abdominal adipose tissue. The high pancreatic 
expression was surprising, given that the gastric glandular mucosa is considered to be the 
predominant source of circulating nesfatin-1 in rats [28] and thus the stomach was expected to 
have the highest level of NUCB2/nesfatin-1 expression in cats as well. There are several possible 
explanations for this result. One possibility is that there are species-specific differences in 
nesfatin-1 expression. The previous studies documenting gastric mucosa as being the primary 
source of circulating nesfatin-1 were performed in rats, so this may not accurately reflect 
expression in cats. Secondly, it is possible some or all the pancreatic mRNA expressed is not 
converted into formed nesfatin-1 protein, and, therefore, will not be a significant contributor to 
circulating nesfatin-1 concentrations. Discordance between NUCB2/nesfatin-1 mRNA and 
protein expression has been documented in cats previously [31], and a study in dogs also 
suggests that changes in mRNA expression may not necessarily reflect changes in circulating 
nesfatin-1 concentrations [30]. Another consideration is that the relative expression between 
tissues may not reflect total mRNA and protein production in the individual tissues. While 
relative gastric expression is lower, the total amount of mRNA and therefore to total amount of 
protein produced may still be higher in the stomach, and, therefore, still represent the major site 
of peripheral nesfatin-1 production. Furthermore, it is unknown if production of nesfatin-1 is 
uniform or compartmentalized throughout the stomach, therefore sampling a small area of the 
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gastric body mucosa could have inadvertently missed more productive areas of mucosa. 
However, this scenario is considered less likely given the magnitude of the difference between 
pancreatic and gastric expression. 
Lastly, the role of pancreatic NUCB2/nesfatin-1 expression must be considered. In vitro 
studies have shown that nesfatin-1 directly increases insulin secretion from pancreatic islet cells 
exposed to hyperglycemic conditions [51], and a local autocrine mode of action for pancreatic 
nesfatin-1 has been hypothesized in rats [66]. As such, NUCB2/nesfatin-1 expressed within the 
feline pancreas may act in a similar manner without significantly contributing to circulating 
nesfatin-1 concentrations.  
 
2.5.2 NUCB2/Nesfatin-1 mRNA Expression in Diabetic Cats 
The most intriguing changes seen were the NUCB2/nesfatin-1 expression in gastric and 
pancreatic tissue in the five diabetic cats, who showed two relatively distinct patterns of 
expression, with two diabetic cats expressing pancreatic and gastric NUCB2/nesfatin-1 at similar 
levels to lean healthy cats, and three diabetic cats have decreased pancreatic and gastric 
expression.  The possible prognostic significance of this biphasic expression needs to be 
investigated further e.g., with an increased number of study subjects. Interestingly, the diabetic 
cats with higher expression both had lean body condition scores (4/9), although the three cats 
with low expression were of variable body condition (6/9, 6/9, and 1/9 respectively). Given this 
variability, it is unlikely that differences in condition score or adiposity had a major effect on the 
differences in mRNA expression in the diabetic cats, though it cannot be excluded. Similarly, the 
two diabetic cats with higher NUCB2/nesfatin-1 expression were spayed females, while two of 
the three diabetic cats with low expression were castrated males. This could suggest some degree 
of sexual dimorphism between NUCB2/nesftin-1 expression, though this is of questionable 
significance given the small sample size. 
Another possibility is that the individual variance in feline pancreatic expression of 
NUCB2/nesfatin-1 may be an indicator of islet health or pancreatic ß-cell function. Previous 
research has found that the anti-hyperglycemic effects of nesfatin-1 are time, dose, and insulin-
dependent [45]. Furthermore, pancreatic nesfatin-1 protein expression was found to be lower in a 
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type 2 diabetic rat model compared with lean healthy rats [66]. It follows that pancreatic 
expression of NUCB2/nesfatin-1 mRNA may be correlated with insulin production and islet 
health. Healthy lean cats may have comparatively better islet health and insulin secretory 
capabilities and, therefore, higher NUCB2/nesfatin-1 expression. In diabetic cats, the progressive 
islet cell loss or continued glucose toxicity and resulting decreased insulin secretion may 
potentially lead to decreased NUCB2/nesfatin-1 expression. Similarly, this could also explain the 
biphasic expression seen in the diabetic cats. The three diabetic cats with reduced 
NUCB2/nesfatin-1 mRNA expression may have comparatively poorer islet cell function in 
comparison to the two diabetic cats that had gastric and pancreatic mRNA expression similar to 
the lean healthy cats. If this is the case, and these two cats did have comparatively better islet cell 
health, it would also suggest these two cats may also have been more responsive to diabetic 
treatment.  
Alternatively, nesfatin-1 has been found to increase insulin secretion in the presence of 
hyperglycemia [51], and higher nesfatin-1 concentrations than those in lean subjects are required 
to stimulate insulin secretion in mice [19]. These findings could suggest the opposite association, 
that increased pancreatic NUCB2/nesfatin-1 expression theoretically represents a compensatory 
attempt to maintain insulin secretion in animals with poor islet cell health and diminished insulin 
secreting capabilities i.e., diabetics. However, this scenario may be considered less likely as if 
this were the case, lean healthy cats would be expected to have low NUCB2/nesfatin-1 
expression, with expression increased in diabetic cats with islet cell damage. Overall, what these 
changes in NUCB2/nesfatin-1 mRNA expression mean in regard to prognostic significance and 
the different expression patterns in diabetic cats requires further investigation. 
 
2.5.3 NUCB2/Nesfatin-1 mRNA Expression Between Lean and Overweight Cats 
In overweight cats, the overall trend in NUCB2/nesfatin-1 tissue expression, particularly 
in pancreatic and gastric tissue, was that mRNA expression appeared to be marginally decreased 
in comparison to lean cats. This trend was unexpected, as previous research in humans has found 
that plasma nesfatin-1 levels and gastric nesfatin-1 protein expression are positively correlated 
with body mass index [29,46]. This increased expression in overweight humans is hypothesized 
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to be a compensatory response by nesfatin-1 to increase anorexigenic signalling [29]. The reason 
for this discrepancy between our findings and the findings in humans is unclear. It may reflect 
that cats do not express nesfatin-1 in the same ways as other species as suggested by a previous 
study [31], or that tissue mRNA or protein expression may not necessarily correlate with 
circulating nesfatin-1 concentrations [30,66]. Speculatively, given that obesity and insulin 
resistance are closely linked, these findings could indicate differences in pancreatic islet health, 
similar to the diabetic cats. If the overweight cats have insulin resistance and poor islet cell 
function, then this could be reflected by a decrease in NUCB2/nesfatin-1. In this way, mRNA 
expression would be altered due to insulin resistance as a result of obesity, rather than as a direct 
response to changes in adiposity. However, given the difficulties in identifying the presence of 
insulin resistance in cats [2], this hypothesis is difficult to prove.  
These results also point towards nesfastin-1 in cats displaying similar characteristics to 
adiponectin, an adipokine whose expression decreases in obese and diabetic people and cats [49]. 
Similar to nesfatin-1, adiponectin is reported to increase insulin sensitivity and peripheral 
glucose uptake [47]. Further investigation into the potential interactions between nesfatin-1 and 
adiponectin expression in cats may be warranted. 
There may be slightly decreased expression in these two tissues amongst the overweight 
and diabetic cats in comparison to the lean cats; however, these expression patterns are of 
questionable significance given the wide variance in expression seen in the lean cat group. The 
lack of a significant pattern in mRNA expression in skeletal muscle and abdominal adipose 
tissue may reflect the fact that these tissues are likely the target of nesfatin-1 activity. Nesfatin-1 
enhances peripheral glucose uptake [61] and improves insulin sensitivity in peripheral tissues 
including skeletal muscle and adipose tissue [37]. Therefore, these tissues are receptive to the 
actions of nesfatin-1 but may not necessarily be important sites of nesfatin-1 production.  
 
2.5.4 Strengths and Limitations  
To our knowledge, this is the first study to evaluate and compare tissue nesfatin-1 mRNA 
expression in lean, overweight, and diabetic cats, and to consider how tissue nesfatin-1 
expression may relate to differences in adiposity and glycemic control in cats. This provides new 
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insight into the role that nesfatin-1 plays in the pathophysiology of obesity and diabetes in cats. 
However, there were some limitations to this study. The main limitation is the sample size. The 
small sample size and the wide variance in tissue expression in all the groups makes it difficult to 
determine whether the changes seen between the lean, overweight, and diabetic cats are truly due 
to changes in glycemic control or adiposity, or due to other confounding factors influencing 
nesfatin-1 expression. For example, increases in plasma nesfatin-1 have been demonstrated in 
human that are hypertensive [55], and human patients with depression have shown increased 
levels of plasma nesfatin-1 [60], though it was not determined how this impacted underlying 
mRNA expression. Hypertension was not specifically evaluated in these cats; however, they did 
not show any evidence of cardiac disease, hyperthyroidism, severe renal disease, or other factors 
that cause hypertension in cats. The lean cats that were sampled were euthanized for apparent 
behavioural reasons, which potentially may have influenced nesfatin-1 expression. However, in 
laboratory animals, the induction of anxiety-like behaviours is only induced by ICV 
administration of nesfatin-1 [41], so there is no conclusive evidence to suggest it would impact 
gastrointestinal nesfatin-1 expression. Furthermore, we were not euthanizing cats specifically for 
the purposes of our study. Because of this, the only lean, otherwise healthy cats that were 
available for us to sample were cats that were euthanized for behavioural reasons, so this issue 
was considered unavoidable.  
Finally, the nutritional status of all cats sampled was not known, and cats were not 
specifically fasted prior to euthanasia. 24 hour fasting has been shown to decrease 
NUCB2/nesfatin-1 mRNA expression in rat gastric endocrine cells [28], indicating that fasting or 
nutritional status has an impact on NUCB2/nesfatin-1 mRNA expression. Therefore, it is 
possible that any potential differences in the fasting status of the cats may have contributed to 
differences in mRNA expression, particularly in the stomach. It is possible that expression in the 
other tissues evaluated could also be affected by fasting status though this is considered less 
likely, particularly in regard to pancreatic expression, given that pancreatic nesfatin-1 may have 
different physiological functions to gastric nesfatin-1. Overall, larger sample sizes would allow 
us to evaluate the variability of expression within these individual groups with greater 
confidence, and therefore provide more support that differences between the groups are primarily 
due to differences in glycemic control and adiposity. 
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2.5.5 Future Studies 
Future studies into nesfatin-1 expression would involve evaluation of additional 
gastrointestinal tissues to create a more holistic picture of NUCB2/nesfatin-1 expression. 
Analysis of mRNA expression in other gastrointestinal tissues, such as the liver or duodenum, 
may help uncover other sites where significant expression is present. Ideally, NUCB2/nesfatin-1 
expression would be analysed in conjunction with formed nesfatin-1 protein expression, as well 
as plasma nesfatin-1 levels in each cat. Nesfatin-1 protein expression could be evaluated by 
immunoreactivity, which would help localize nesfatin-1 expression within the feline pancreas 
and other tissues. Histological examination of pancreatic tissue to evaluate the degree of islet cell 
pathology could also be pursued concurrently.  Assessing mRNA and protein expression 
concurrently may be of particular benefit in cats given the previously identified discordance 
between NUCB2/nesfatin-1 mRNA expression and nesfatin-1 protein expression. Concurrent 
mRNA and protein expression evaluation would identify whether the changes in mRNA 
expression could result in changes in protein expression, and if this discordance between mRNA 
and protein expression in lean cats is also seen in overweight and diabetic cats. Concurrent 
measurement of plasma concentrations would assess whether the changes in tissue expression 
reflect changes that occur in peripheral nesfatin-1 concentrations. This would be of particular 
importance to further characterize the changes in pancreatic expression. If changes in pancreatic 
expression do not change in conjunction with changes in peripheral nesfatin-1, then it would 
suggest pancreatic expression does not significantly influence circulating nesfatin-1 and would 
instead hint at localized activity. 
For examining peripheral tissues i.e., skeletal muscle and adipose tissue, which are the 
targets of nesfatin-1 and may not necessarily be major sites of nesfatin-1 production, it may be 
more valuable to assess changes in expression of the nesfatin-1 receptor, once it has been 
identified. More significant differences may be apparent in peripheral tissues of lean, 
overweight, and diabetic cats once expression of the receptor is evaluated. 
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2.5 Conclusion 
In conclusion, the results of this study show there are differences in NUCB2/nesfatin-1 
mRNA expression, particularly in gastric and pancreatic tissue and in diabetic cats. These 
patterns of expression could reflect changes in local pancreatic islet cell health and function in 
these cats. Diabetic cats appear to show a biphasic pattern of expression, with some diabetic cats 
maintaining NUCB2/nesfatin-1 expression similar to lean controls. Further investigation into 
changes in mRNA expression in feline gastrointestinal tissues, in conjunction with analysis of 
nesfatin-1 protein expression and circulating nesfatin-1 levels are needed to evaluate the 
significance of these changes in expression. 
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Transition 
The previous chapter of this thesis evaluated tissue expression of NUCB2/nesfatin-1 
mRNA expression in cats. We have also evaluated circulating concentrations of nesfatin-1 in 
lean, overweight, and diabetic cats, and this information is presented in the following chapter. 
The concurrent evaluation of circulating plasma nesfatin-1 concentrations allows us to 
demonstrate a more complete picture of nesfatin-1 expression in cats, and to further investigate 
the role of nesfatin-1 in the development of obesity and diabetes mellitus. 
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Chapter Three: Are Differences in Plasma Nesfatin-1 Concentrations in Cats Associated 
with Differences in Body Weight and Glycemic Control? 
 
3.1 Abstract 
Background: Obesity and diabetes mellitus are increasing issues in humans and 
domestic cats. Diabetes mellitus in cats shares similar clinicopathologic features to type 2 
diabetes mellitus in humans. Nesfatin-1 is a recently discovered protein hormone that has been 
implicated in the development of obesity and diabetes, and alterations in plasma nesfatin-1 
concentrations have been documented in type 2 diabetic humans. This study aimed to evaluate 
whether plasma nesfatin-1 concentrations in cats were associated with adiposity or insulin 
resistance, and to determine if nesfatin-1 concentrations were altered by diabetic treatment. 
Influences of sex and age on nesfatin-1 concentrations were also assessed. 
Methods: Case control study. Plasma was collected from 13 lean and 13 obese non-
diabetic cats, and eight newly diagnosed and five long term diabetic cats. Newly diagnosed 
diabetic cats were sampled before and after four weeks of diabetic treatment. Plasma nesfatin-1 
levels were measured by a rat nesfatin-1 ELISA, which was validated for use with feline plasma.  
Results: Median plasma nesfatin-1 concentrations in newly diagnosed and long-term 
treated diabetic cats showed a slight upward trend in comparison to lean and overweight non-
diabetic cats, though the highest nesfatin-1 concentrations were seen in a subset of lean healthy 
cats. However, overall differences in plasma nesfatin-1 concentrations in lean, overweight, and 
diabetic cats were not statistically significant. Sex and age were also not significantly associated 
with plasma nesfatin-1 levels. Newly diagnosed diabetic cats showed a statistically significant 
decrease in nesfatin-1 concentrations following short-term treatment, which may suggest a link 
between decreased nesfatin-1 concentrations and diabetic treatment in cats.  
Conclusions: Our results suggest that changes in plasma nesfatin-1 concentrations may 
be more related to diabetic status and the presence of insulin resistance as opposed to differences 
in adiposity or body condition, though further research is required to determine the significance 
of this relationship. There may be additional, currently unknown factors that increase nesfatin-1 
concentrations in cats. Future studies may include longitudinal studies to investigate if nesfatin-1 
concentrations change as cats develop increasing adiposity, insulin resistance, and eventually 
become clinically diabetic. 
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3.2 Introduction 
 
The prevalence of obesity and obesity-related diabetes mellitus is increasing in both 
humans and cats [1]. Treatment of diabetic cats involves the administration of exogenous insulin 
and a high protein, low carbohydrate diet, as these diets are associated with reduced post prandial 
glucose and insulin concentrations [5]. However, management requires significant investments in 
time, money, and effort. This is not always feasible for owners and it is estimated around 30% of 
cats are euthanized within a year of diagnosis [4]. The ideal treatment outcome is the 
achievement of diabetic remission, defined as the maintenance of normoglycemia without the 
administration of exogenous insulin for at least four weeks [4]. However, remission rates are 
variable, ranging from 20 to 80% [6–8]. Another issue is that currently, no reliable marker exists 
to help identify cats that have a higher chance of remission, or to identify cats with insulin 
resistance that are not diabetic i.e., prediabetics [2,4]. If insulin resistance could be identified 
before diabetes occurs, treatment may be less laborious, avoiding the need for exogenous insulin 
or glucose monitoring. Similarly, if cat’s that have a higher chance of achieving diabetic 
remission could be identified before starting treatment, this may provide added motivation to 
pursue aggressive treatment. Nesfatin-1 may have potential as such a marker. 
Changes in circulating nesfatin-1 concentrations have been investigated in humans with 
obesity and diabetes mellitus. Plasma nesfatin-1 concentrations increase as body fat percentage 
increases in humans [46], and increases in plasma nesfatin-1 were also noted in people with 
newly diagnosed type 2 diabetes mellitus (T2DM) and those with impaired glucose tolerance i.e., 
prediabetics [52]. Nesfatin-1 has been shown to subsequently decrease in T2DM patients 
receiving treatment, suggesting a link between peripheral nesfatin-1 concentrations and both the 
development of T2DM and the resumption of adequate glycemic control [63]. IV injections of 
nesfatin-1 in mice have been shown to reduce blood glucose, but only in hyperglycemic states 
[45]. Furthermore, glucose, insulin, and nesfatin-1 levels were significantly higher in humans 
with impaired glucose tolerance, than healthy controls [54]. This suggests that increased 
nesfatin-1 concentrations may act as a compensatory mechanism, with plasma concentrations 
increasing in an attempt to maintain insulin function and glucose homeostasis when insulin 
sensitivity is impaired. The majority of cases of diabetes mellitus in cats share similar 
pathophysiological mechanisms to T2DM in humans i.e., insulin resistance and pancreatic ß-cell 
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dysfunction [2,4]. Thus, nesfatin-1 may play an important role in the development of obesity and 
diabetes mellitus in cats as well. 
Despite the increasing prevalence of obesity and diabetes in cats, the role that nesfatin-1 
plays in the pathogenesis of these conditions in cats is not well understood. A recent study has 
shown nesfatin-1 to be highly conserved amongst domestic species (greater than 90% similarity 
of the amino acid sequence in the bioactive core) and plasma nesfatin-1 concentrations in cats 
have been successfully measured using a commercially available ELISA [31]. Thus, the primary 
objectives of this study were the validation of a commercially available rat nesfatin-1 ELISA for 
use with feline plasma, and to investigate whether plasma nesfatin-1 concentrations differ 
between lean and overweight non-diabetic cats, and newly diagnosed diabetic cats. Secondary 
objectives included assessment of the effects of short-term and long-term diabetic therapy on 
plasma nesfatin-1 concentrations, and the comparison of plasma nesfatin-1 concentrations to 
other markers of adiposity and glycemic control including body weight, body condition score, 
serum glucose, serum fructosamine, and serum cholesterol. Given the associations between 
plasma nesfatin-1, adiposity and glycemic control in other species, we hypothesized that lean, 
overweight, and diabetic cats would have differing concentrations of plasma nesfatin-1. 
Nesfatin-1 concentrations were expected to be increased in overweight cats compared with lean 
cats, with higher concentrations in newly diagnosed diabetic cats compared to both lean and 
overweight non-diabetic cats. We also hypothesized that nesfatin-1 concentrations would 
decrease following short and long-term diabetic treatment.  
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3.3 Materials and Methods 
3.3.1 Study Design, Case Selection and Control Groups 
A case control study was performed. Forty-one cats were recruited through the Western 
College of Veterinary Medicine (WCVM) Veterinary Medical Centre. Animal use was approved 
by the University of Saskatchewan Animal Research Ethics Board (Animal Use Protocol 
Number 20190051). Inclusion criteria involved body condition score (BCS), age, amenability to 
restraint and venipuncture, and no prior history of behavioural disorders or cardiac disease. 
Exclusion criteria for all cats included cats that were not amenable to restraint without sedation, 
or those with evidence of pancreatic or systemic neoplasia. 
Cats were placed into four separate study groups depending on their BCS or the presence 
of diabetes mellitus. Lean and overweight cats were recruited based on BCS; lean cats with a 
BCS of 4 or 5/9, and overweight cats with a BCS of 7 to 9/9 [67]. All condition scoring was 
performed by a single investigator (ES). Lean and overweight cats were confirmed as healthy by 
a clinical history, physical examination, and routine laboratory testing. Laboratory testing 
included a manual complete blood count, serum biochemistry, total thyroid hormone (tT4), 
serum fructosamine, and dipstick urinalysis. Exclusion criteria for lean and overweight cats 
based on laboratory findings included a moderate to marked anemia, inflammatory leukogram, 
moderate increases in ALP, ALT, and GGT, moderate hypercholesterolemia (>10 mmol/L), 
moderate hyperglycemia (>12 mmol/L), IRIS stage three or four renal disease, or 
hyperthyroidism. Thirteen lean cats were enrolled in the study. Fourteen overweight cats were 
initially enrolled, and one was subsequently excluded due to hyperthyroidism, so 13 overweight 
cats were included overall. 
Diabetic cats were enrolled regardless of BCS. A clinical history, physical exam, 
screening blood work and urinalysis were also performed. A diagnosis of diabetes mellitus was 
based on clinical history and supportive laboratory findings including hyperglycemia (>12 
mmol/L), glucosuria, and elevated fructosamine (>347 umol/L). Newly diagnosed diabetic cats 
were eligible for enrolment if they had not started insulin therapy or had been receiving insulin 
for less than one week. Long term diabetic cats were defined as being initially diagnosed with 
diabetes at least six months prior to enrolment. Exclusion criteria for new and long-term diabetic 
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cats included moderate to marked anemia, inflammatory leukogram, IRIS stage three or four 
renal disease, hyperthyroidism, and cats who developed diabetes as a result of recent 
glucocorticoid therapy. Nine newly diagnosed diabetic cats were initially enrolled, and one was 
excluded due to the discovery of pancreatic neoplasia, so eight newly diagnosed diabetic cats 
were included overall. Five long term diabetic cats were also enrolled in the study. 
 
3.3.2 Blood and Urine Collection  
Blood was collected once from lean, overweight, and long-term diabetic cats, while blood 
was collected twice from newly diagnosed diabetic cats. All blood was collected after cats were 
fasted for 8 to 12 hours and refrigerated at 4C within 10 minutes of collection. Plasma samples 
for nesfatin-1 analysis were collected in EDTA tubes (Ref 367841; Becton Dickinson and 
Company, NJ) and serum samples for biochemistry, tT4, and fructosamine were collected into 
serum separator tubes (Ref 367983; BD, NJ). Urine was collected via ultrasound guided 
cystocentesis. For all diabetic cats, blood glucose and ketone levels were analyzed by a handheld 
glucometer (Alpha Trak 2, Abbott, CA) and ketometer (Freestyle Optimum Neo, Abbott, CA) 
immediately following collection. PCV and TP were measured along with a Kwik DiffTM 
(catalogue number 9990701; Thermo Scientific, WA) stained blood smear for manual slide 
evaluation. Plasma and serum were centrifuged within 30 minutes of collection and stored at -
80C until required. Urine was analysed within 30 minutes or stored at 4C and warmed to room 
temperature before analysis. Urine specific gravity was measured by refractometry, and chemical 
constituents were measured by dipstick (Chemstrip 9, Roche, Quebec). If abnormalities were 
found on the dipstick e.g., hematuria or proteinuria, the urine sediment was assessed 
cytologically. 
Newly diagnosed diabetic cats at their first appointment were prescribed exogenous 
insulin administration and dietary modifications. Seven cats were started on Lantus Toujeo® 
insulin pens 2 IU BID, and one cat was prescribed Glargine® insulin as it had already been 
started four days prior to enrolment. Seven diabetic cats were switched to Purina® Diabetic 
Management food after a five-day transition from their original diet. One cat was placed on 
Purina® NF Renal Function food due to concurrent IRIS stage two renal disease. 
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The second appointment for the newly diagnosed diabetic cats occurred four to five 
weeks after the first appointment. Blood was collected into EDTA and serum separator tubes, 
then processed and stored as previously described. Serum was submitted for repeat cholesterol 
and fructosamine measurement. A subcutaneous glucose monitoring device (Freestyle Libre, 
Abbott, CA) was fitted, and interstitial glucose readings were recorded digitally for up to 14 
days. Interstitial glucose was recorded as an average of the first three days of measurement, so 
that glucose levels were representative of glycemic control closer to the time of the second blood 
collection. 
 
3.3.3 Validation of the Nesfatin-1 ELISA 
Assay validation was performed using plasma samples from lean and overweight cats 
collected as part of an unrelated study involving collaborators at the University of Calgary 
Faculty of Veterinary Medicine (UCVM) and the WCVM. All samples were stored at -80oC. 
Validation was performed on a rat nesfatin-1 ELISA kit (catalogue number EK-003-22; Phoenix 
Pharmaceuticals Inc, CA) run in accordance with manufacturer’s instructions. As purified feline 
nesfatin-1 is not commercially available, feline plasma samples were run individually to 
determine their concentrations, and then pooled to create low, medium, and high concentration 
samples. 
Assay precision was determined using the pooled samples. Intra-assay coefficient of 
variation (CoV) was calculated by running the pooled samples five times in duplicate. Inter-
assay CoV was assessed by running pooled samples five times on five different days in 
duplicate. Targeted intra and inter-assay CoV was less than 10%. Assay accuracy was measured 
by sample parallelism, linearity under dilution, and a modified spiked recovery test. Parallelism 
was assessed using three individual feline plasma samples. Sample concentration was measured 
in duplicate, then serially diluted (3:4, 1:2, 1:4, 1:8) with expected values compared to the 
measured values. For the spiked recovery test, two individual feline plasma samples were used as 
purified feline nesfatin-1 is not commercially available. The samples were mixed in three ratios 
(1:5, 1:1, and 4:5) and analysed in duplicate, and expected results were compared to the 
measured values. Limit of detection was calculated from five replicated zero standards (assay 
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buffer) as a mean plus three standard deviations. For test parallelism, a sample recovery of 70 to 
130% was targeted for the measured dilutions in comparison to the expected values. An r2 value 
of greater than 0.95 was targeted for linearity under dilution. For the modified spiked recovery 
test, we targeted a sample recovery of 80 to 120%. 
 
3.3.4 Feline Plasma Nesfatin-1 Measurement 
All plasma samples were run with the previously mentioned rat nesfatin-1 ELISA 
(catalogue number EK-003-22; Phoenix Pharmaceuticals Inc, CA) according to manufacturers’ 
instructions. Feline plasma was thawed and centrifuged at 10,000 x g for 10 minutes to 
precipitate any visible lipemia present [68]. Thirty microlitres of each sample was taken and 
combined with 90 uL of the assay buffer in a separate Eppendorf tube for a 1:4 dilution.  
 
3.3.5 Statistical Analysis 
Descriptive statistics for nesfatin-1 levels in the lean, overweight, and diabetic cats were 
evaluated. Normal distribution of plasma nesfatin-1 levels was assessed by a Shapiro-Wilk test. 
Plasma nesfatin-1 concentrations were compared between the original study groups, lean cats, 
overweight cats, and newly diagnosed diabetic cats at their initial presentation. The effects of 
body condition and diabetes were then assessed individually. BCS was transformed into a 
categorical variable, with cats classified as either being lean (BCS less than 6/9), or overweight 
(BCS greater than or equal to 6/9), regardless of diabetic status. All overweight non-diabetic cats 
had a BCS greater than or equal to 7/9, a single diabetic cat had a BCS of 6/9. For diabetic status, 
cats were classified as either diabetic or non-diabetic, regardless of their body condition. Cats 
were classified as young (less than six years of age), middle age (6 to 9 years of age), or old 
(greater than nine years of age). Differences in plasma nesfatin-1 according to group, body 
condition, diabetic status, age, and sex were assessed by a Kruskal-Wallis ANOVA. Associations 
between plasma nesfatin-1 and fructosamine, glucose, body weight, and cholesterol were 
evaluated with linear regression. Further interactions between individual continuous and 
categorical variables were assessed by multivariate regression analysis. Variables were included 
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in the multiple regression model if their P-value was less than 0.3, and the significance of these 
different models was assessed in comparison to a null model by likelihood ratio. Correlations 
between these variables were assessed by the variance inflation factor (VIF). 
Statistical analysis was performed without the four samples that had the highest plasma 
nesfatin-1 concentrations, as these samples were considered potential outliers. This data was 
assessed similarly as above, though without these four values the data was normally distributed. 
Plasma nesfatin-1 levels were compared between lean, overweight and diabetic cats by a one-
way ANOVA with Bonferroni correction. Differences in nesfatin-1 according to body condition, 
age, diabetic status, and sex were compared with a t-test. Associations between plasma nesfatin-1 
and fructosamine, glucose, body weight, and cholesterol were assessed by linear regression, and 
multivariate regression analysis was performed.  
Descriptive statistics for analysis of nesfatin-1 concentrations in diabetic cats before and 
after four weeks of treatment were performed and normality was assessed with a Shapiro-Wilk 
test. One cat had a fructosamine concentration far lower than what was expected clinically, and 
this fructosamine values was not included in the statistical analysis as analytical or laboratory 
error could not be excluded. Changes in nesfatin-1, body weight, glucose, and fructosamine were 
assessed with a paired t-test, and changes in cholesterol were assessed by a Wilcoxon Signed-
Rank Test. Associations between changes in nesfatin-1 concentrations and changes in body 
weight, fructosamine, glucose, and cholesterol were assessed by linear regression. Multivariate 
regression was performed as to assess if there were significant interactions between variables. 
Statistical significance for all tests was set at P < 0.05 
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3.4 Results 
3.4.1 Nesfatin-1 ELISA Validation Results 
The nesfatin-1 ELISA kit used in this study showed acceptable validation characteristics 
when using feline plasma, though dilution of the samples created additional variation. The 
undiluted feline nesfatin-1 plasma concentrations were frequently higher than the listed linear 
range of the assay (linear range 0.92 – 12.7 ng/mL). Despite this, the intra and inter-assay CoVs 
were all well within the targeted CoV of less than 10% in the low, medium, and high 
concentration samples (Table 2.1). The modified spiked recovery test showed an acceptable 
average sample recovery of 106% (Table 2.1). Serial dilution of three unknown samples with the 
assay buffer displayed linearity under dilution (slope r2 > 0.95). However, these serial dilutions 
showed increasing sample recovery percentage in comparison to the expected nesfatin-1 
concentration (Table 2.2), i.e., relative sample recovery increases as a dilution factor increases. 
This increasing recovery is consistent with a negative matrix effect associated with the feline 
plasma, and at higher dilutions (1:2 or greater) the variation was higher than the target 
parallelism of 70 to 130%. As this matrix effect showed different degrees of strength at different 
dilutions, all subsequent plasma samples were run with the same dilution factor (1:4). This 
dilution factor was chosen to ensure measured nesfatin-1 concentrations fell within the linear 
range of the assay. The variable matrix effect associated with dilution may limit use of the assay 








 - 54 - 
 
 
Table 3.1: Intra-assay and inter-assay variation, limit of detection, and modified spiked recovery 
test for feline nesfatin-1 samples using a rat nesfatin-1 ELISA. Intra and Inter-assay CoVs were 
determined with pooled feline plasma samples of Low, Medium, and High nesfatin-1 
concentrations 
 
Sample Dilution Sample 1 Recovery % Sample 2 Recovery % Sample 3 Recovery % Mean % 
1:1 - - -  
3:4 116 121 120 119 
1:2 135 144 135 138 
1:4 182 181 214 192 
1:8 194 224 281 233 
Slope r2 0.97 0.96 0.97  
Table 3.2: Linearity under dilution (r2) and parallelism of nesfatin-1 concentrations (Measured 
concentration divided by the expected or calculated nesfatin-1 concentration for each dilution) 
for three separate feline plasma samples 
  
 Intra-Assay Variation Inter-Assay Variation 
Low Medium High Low Medium High 
Mean concentration (ng/mL) 10.6 17.86 23.87 12.83 21.09 27.19 
Coefficient of Variation (%) 3.62 4.42 3.77 6.45 1.7 2.02 
Limit of Detection (ng/mL) 0.32      
Modified Spiked Recovery Test 
Average Sample Recovery 
 
106% 
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3.4.2 Plasma Nesfatin-1 Levels in Lean, Overweight and Diabetic Cats 
The most striking feature seen in the initial data between the defined groups was the 
increased variance in the lean cat group (Figure 3.1 and Table 3.3) (variance = 7.4), which was 
higher than any other group (variance ranged from 0.5 – 0.7). The observed median plasma 
nesfatin-1 concentrations were lowest in the lean and overweight cat groups. However, the cats 
with the four highest individual plasma nesfatin-1 concentrations were all in the lean cat group. 
Observed median nesfatin-1 concentrations in newly diagnosed (5.8 ng/mL) diabetic cats were 
slightly higher than both lean and overweight non-diabetic cats, though this difference was not 
statistically significant (P = 0.21). Median plasma nesfatin-1 concentrations in long-term diabetic 
cats (6.4 ng/mL) were also higher than both lean and overweight, non-diabetic cats, though this 











Figure 3.1: Plasma nesfatin-1 concentrations in lean (n = 13) and overweight (n = 13) non-
diabetic cats from an owned cat population, and newly diagnosed (n = 8) and long-term (n = 5) 
diabetic cats referred to the Western College of Veterinary Medicine Veterinary Medical Centre 
between August 2019 and March 2020. 
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3.4.3 Relationship Between Plasma Nesfatin-1 and Other Patient Variables 
Plasma nesfatin-1 levels in all cats were assessed in relation to characteristics associated 
with adiposity and glycemic control. Overall, no individual variable showed a statistically 
significant relationship to plasma nesfatin-1 concentrations (Table 3.3). The closest relation seen 
was that of plasma nesfatin-1 concentrations and diabetic status (P = 0.11), followed by group (P 
= 0.21) and body condition (P = 0.33). A poor relationship was seen with plasma nesfatin-1 and 
body weight (coefficient -0.3, P = 0.1, linear regression). This model also had low r2 value (0.09) 
and lacked normally distributed residuals. Nesfatin-1 was not found to be associated with serum 
cholesterol (coefficient 0.01, P = 0.5, linear regression), serum fructosamine (coefficient -0.01, P 
= 0.96, linear regression) and serum glucose (coefficient -0.01, P = 0.98, linear regression). 
Multivariate regression analysis was attempted including the body weight and diabetic status 
variables. The ‘Group’ variable was not included in multi-variate analysis as this variable 
combines the effects of changes in body weight/ body condition and diabetic status. Using 
multivariate regression, a model with significant independent risk factors could not be created 
and no significant associations between variables and nesfatin-1 concentrations were seen. No 










 - 57 - 
Characteristics 
of cats in the 
study 
Characteristic Sub-Category Median Plasma Nesfatin-1 
(Min-Max) (ng/mL) 
Variance P-Value 
Group Lean (n = 13) 5.1 (4 – 12.6) 7.4 0.21 
Overweight (n = 13) 5.1 (3.6 – 6.4) 0.7  
Newly Diagnosed Diabetic (n = 8) 5.8 (4.9 – 7.2) 0.6  
Long Term Diabetic (n = 5)* 6.4 (5.3 – 6.7) 0.5 0.16 
 
Diabetic Status Non-Diabetic (n = 26) 5.1 (3.6 – 12.6) 4.4 0.11 




Less Than 6/9 (n = 18) 5.3 (4 – 12.6) 5.4 0.33 
Greater Than or Equal To 6/9 (n = 16) 5.1 (3.6 – 6.4) 0.6  
 
Age Less than 6 years of Age (n = 11) 4.7 (3.9 – 9.7) 2.6 0.4 
6-9 Years of Age (n = 14) 5.2 (4.1 – 12.6) 5.3  
Greater than 9 Years of Age (n = 9) 5.4 (3.6 – 8.2) 1.9  
 
Sex Male (n = 20) 5.4 (3.6 – 8.2) 1.4 0.38 
Female (n = 14) 5.0 (3.9 – 12.6) 4.8  
Table 3.3: Associations between plasma nesfatin-1 concentrations and selected characteristics of 
lean and overweight non-diabetic cats, and newly diagnosed diabetic cats from an owned cat 
population referred to the Western College of Veterinary Medicine Veterinary Medical Centre 
between June 2019 and March 2020, Kruskal-Wallis ANOVA. 
*The long-term diabetic cats (n = 5) were not included in the ANOVA analysis and are presented 
in this table for descriptive purposes only 
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3.4.4 Plasma Nesfatin-1 Data Without Potential Outliers 
To understand the influence of the four extreme values of nesfatin-1 in the lean group on 
the overall analysis a subset analysis was run excluding them (Table 3.4). These four lean cats 
had plasma nesfatin-1 concentrations of 8.2, 9.4, 9.7, and 12.6 ng/mL respectively. In this subset 
analysis there was a statistically significant association found between nesfatin-1 concentrations 
and diabetic status (P = 0.01), and between nesfatin-1 concentrations in the lean cat and newly 
diagnosed diabetic cat group (P = 0.02). An association was also found between plasma nesfatin-
1 concentrations and both fructosamine (Co-efficient 0.3, P = 0.01, linear regression) and 
glucose (Co-efficient 0.3, P = 0.03, linear regression). There were poor associations seen 
between nesfatin-1 and cholesterol (Co-efficient 0.06, P = 0.28, linear regression), and nesfatin-1 
and body weight (Co-efficient -0.07, P = 0.44, linear regression). Multivariate regression was 
attempted including diabetic status and serum cholesterol as variables. Fructosamine and glucose 
were not included, as the variable ‘diabetic status’ is defined by changes in glucose and 
fructosamine. Therefore, these variables are considered colinear, with diabetic status being an 
intermediary variable. This multivariate model was not significant according to likelihood ratio, 
though cholesterol was found to be a confounding variable for diabetic status. Diabetic status 
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Table 3.4: Correlations between plasma nesfatin-1 concentrations and selected characteristics of 
lean and overweight non-diabetic cats from an owned cat population, and newly diagnosed 
diabetic cats referred to the Western College of Veterinary Medicine Veterinary Medical Centre 
between August 2019 and March 2020, One-Way ANOVA with Bonferroni correction (Group), 
and t-test (Diabetic status, body condition, age, sex). The four highest individual plasma 
nesfatin-1 concentrations have been omitted, and the long-term diabetic cats (n = 5) were not 
included in the statistical analysis. 
Variable Variable Sub-Category Median Plasma Nesfatin-1 
(Min-Max) (ng/mL) 
Variance P-Value 
Group Lean (n = 9)  4.7 (4 – 5.6) 0.3 0.02 
Overweight (n = 13) 5.1 (3.6 – 6.4) 0.7  
Newly Diagnosed Diabetics (n = 8) 5.8 (4.9 – 7.2) 0.6  
                                                               Bonferroni Correction Values        Lean    Overweight 
                                                                Newly Diagnosed Diabetic               0.02            0.07 
                                                                Lean                                                                         1 
 
Diabetic Status Non-Diabetic (n = 22) 4.8 (3.6 – 6.4) 0.5 0.01 




Less Than 6/9 (n = 14) 5.0 (4 – 7.2) 0.8 0.85 
Greater Than or Equal To 6/9 (n = 16) 5.1 (3.6 – 6.4) 0.6  
 
Age Less than 5 years of Age (n = 10) 4.6 (3.9 – 6.0) 0.6 0.35 
6-9 Years of Age (n = 12) 5.1 (4.1 – 6.4) 0.4  
Greater than 9 Years of Age (n = 8) 5.2 (3.6 – 7.2) 1.2  
 
Sex Male (n = 17) 5.2 (3.9 – 6.4) 0.6 0.76 
Female (n = 13) 5.0 (3.6 – 7.2) 0.8  
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3.4.5 Changes in Plasma Nesfatin-1 Concentrations and Other Variables in Diabetic 
Cats at Initial Presentation and After Four Weeks of Diabetic Treatment 
Nesfatin-1 levels in diabetic cats before and after treatment showed similar, small levels 
of variance between the pre- and post-treatment nesfatin-1 concentrations. Median plasma 
nesfatin-1 concentrations before treatment were higher than concentrations following treatment 
(5.8 ng/mL pre-treatment, 4.7 ng/mL post-treatment, Figure 3.2 and Table 3.5) and all eight 
individual cats had higher nesfatin-1 levels before treatment. This decrease in nesfatin-1 
concentrations following treatment was statistically significant (P < 0.01) (Table 3). A 
statistically significantly increase in body weight (P <0.01) was seen, along with statistically 
significant decreases in glucose (P <0.01), fructosamine (P <0.01), and cholesterol (P = 0.01) 












Figure 3.2: Plasma nesfatin-1 concentrations of newly diagnosed diabetic cats (n = 8) presenting 
to the WCVM between August 2019 and March 2020, before treatment and after four weeks of 
diabetic treatment (P <0.01), Paired t-test 
P < 0.01 
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Group  Median Plasma Nesfatin-1 (Min – Max) (ng/mL) Variance 
Diabetic Pre-Treatment 5.8 (4.9 – 7.2) 0.6 
Diabetic Post-Treatment 4.7 (4.3 – 6.4) 0.8 
 
Difference Pre & Post Tx Mean Diff Std Dev 95% CI P-Value 
Nesfatin-1 (ng/mL) -0.8 0.5 -1.2 - -0.4 <0.01 
Weight (kg) 0.4 0.3 0.2 – 0.6 <0.01 
Glucose (mmol/L) -14 7.5 -20 - -7.3 <0.01 
Fructosamine (umol/L) -170 80 -238 - -105 <0.01 
Cholesterol (mmol/L) -1.7 - - 0.01 
Table 3.5: Plasma nesfatin-1 concentrations in newly diagnosed client owned diabetic cats (n = 
8) presenting to the WCVM between August 2019 and March 2020, before and after four weeks 
of diabetic treatment, and differences in selected variables in these cats following diabetic 
treatment, Paired t-test (nesfatin-1, Weight, Glucose, Fructosamine) and Wilcoxon Signed-Rank 
test (Cholesterol) 
 
3.4.6 Correlations Between Changes in Plasma Nesfatin-1 and Changes in Other 
Variables 
Changes in plasma nesfatin-1 concentrations before and after treatment were compared to 
changes in body weight, fructosamine, glucose, and cholesterol (Table 3.6). The closest 
correlation was seen with changes in glucose (coefficient -0.45, P = 0.09, linear regression), with 
slight associations seen with changes in fructosamine (coefficient -0.39, P = 0.26, linear 
regression) and changes in body weight (coefficient -1, P = 0.19, linear regression). No 
correlation was apparent with cholesterol (coefficient 0.003, P = 0.98, linear regression). 
Multivariable regression analysis was performed, including glucose and fructosamine. Changes 
in fructosamine were highly correlated with changes in body weight (VIF = 12). Improved 
glycemic control (reflected by fructosamine) was considered to be an independent variable, 
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whereas the increase in body weight is dependent on improved glycemic control, therefore 
fructosamine was included in the model at the expense of body weight. No multivariate models 
were significant and no significant independent risk factors were identified (data not shown). 
 
 
Table 3.6: Correlations between the changes in plasma nesfatin-1 concentrations and changes in 
selected variables in newly diagnosed diabetic cats at their initial presentation and following four 
weeks of treatment, linear regression. 
  
Variables Coefficient 95% CI P-Value (r2) 
Nesfatin-1 with Weight -1.0 -2.7 – 0.66 0.19 (0.27) 
Nesfatin-1 with Fructosamine -0.39 -1.2 – 0.39 0.26 (0.25) 
Nesfatin-1 with Glucose -0.45 -0.99 – 0.09 0.09 (0.41) 
Nesfatin-1 with Cholesterol 0.003 -0.39 – 0.40 0.98 (<0.01) 
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3.5 Discussion 
This study evaluated plasma nesfatin-1 concentrations in lean, overweight, and diabetic 
cats, and a rat nesfatin-1 ELISA was validated for use with feline plasma. The results of this 
study demonstrated a statistically significant decrease in plasma nesfatin-1 concentrations 
following treatment of newly diagnosed diabetic cats. No statistically significant differences in 
plasma nesfatin-1 concentrations were seen between lean and obese non-diabetic cats, and newly 
diagnosed diabetic cats, though overall plasma nesfatin-1 concentrations appeared marginally 
increased in diabetic cats in comparison to non-diabetic cats. However, the four highest 
individual plasma nesfatin-1 concentrations occurred in lean cats. 
 
3.5.1 Plasma Nesfatin-1 Concentrations in Lean Cats 
We found greater variance in plasma nesfatin-1 concentrations in lean cats compared to 
the other groups. While the median nesfatin-1 concentrations in the lean and overweight groups 
were below those of the newly diagnosed and long-term diabetics, the four highest nesfatin-1 
concentrations in individual cats were all in the lean cat group. A laboratory error for these 
values was considered highly unlikely as there were no major discrepancies between the 
duplicate samples. The high concentration samples were also positioned in three separate 
columns, so an error in plate washing was considered unlikely. The variance in nesfatin-1 
concentrations in this lean cat group is generally higher than the variance seen in nesfatin-1 
concentrations from control groups in human diabetic studies [52,53,62], though a direct 
comparison of variance is difficult given that plasma nefatin-1 concentrations in cats appear to be 
much higher than in humans.  
Interestingly, two of the four highest concentrations came from cats that lived in the same 
household, which may suggest an environmental link. However, one cat with a high nesfatin-1 
concentration lived with a cat whose nesfatin-1 levels were closer to the median concentration. 
Follow up was conducted into all cats that were enrolled in our study approximately 18 months 
after sampling, and no associations (behavioural, medical, or dietary) could be found between 
these cats with high nesfatin-1 concentrations. Three of the cats had been clinically well in the 
year since sampling, while one cat was diagnosed with pododermatitis one month after sampling, 
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and also developed a lower urinary tract obstruction six months after sampling. The underlying 
cause of these high nesfatin-1 concentrations is not apparent, though it may suggest there are 
reasons other than body condition and alterations in glycemic control that can unpredictably 
influence plasma nesfatin-1 concentrations. Interestingly, a previous study documented a 
population of lean cats that had low insulin sensitivity, and were therefore at increased risk of 
developing obesity and impaired glucose tolerance [69]. Speculatively, if nesfatin-1 
concentrations are related to differences in glycemic control, then these cats with increased 
nesfatin-1 concentrations could reflect a population of lean cats with comparatively decreased 
insulin sensitivity. However, if this were the case, it would be expected that similarly high 
nesfatin-1 concentrations should be seen in the individual diabetic cats i.e., cats that should have 
significantly decreased insulin sensitivity. It is also possible that these high nesfatin-1 
concentrations could also be seen in overweight and diabetic cats, but given the small sample 
size of our study were not present in the subset of overweight and diabetic cats. 
 
3.5.2 Plasma Nesfatin-1 Concentrations in Overweight Cats 
No significant differences in nesfatin-1 concentrations were identified in overweight cats 
in comparison to lean cats. It was expected that nesfatin-1 concentrations would be increased in 
overweight or obese non-diabetic cats given that obese humans have increased nesfatin-1 levels 
compared with healthy controls [46]. However, the overweight cats in our study had similar 
nesfatin-1 concentrations to the lean cats, suggesting that obesity may not have as much of an 
effect on plasma nesfatin-1 in cats. There are several potential reasons for this. The differences 
between lean and overweight cats may be small, in which case a larger sample size would be 
required to demonstrate a difference. Additionally, it is known that cats compensate for the 
insulin resistance for long periods of time, and the presence of insulin resistance in cats is 
difficult to identify [2]. No reliable marker of insulin resistance is currently available in cats, as 
methods used in humans e.g., intravenous glucose tolerance testing or endogenous insulin 
concentrations, are unreliable for use in cats [2]. Therefore, it is possible that the overweight cats 
enrolled in our study did not have significant insulin resistance or were already compensating 
adequately for any insulin resistance present, in which case nesfatin-1 concentrations may not be 
altered. On follow up 18 months after sampling, no overweight cats had developed diabetes 
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mellitus. Future long-term longitudinal studies following lean and overweight or obese cats 
would be helpful to determine if there are significant differences or changes in nesfatin-1 
concentrations between cats that develop diabetes and those that do not. If so, nesfatin-1 may be 
useful as a proxy for identifying insulin resistance as it develops, and potentially before the 
development of clinical diabetes.  
 
3.5.3 Plasma Nesfatin-1 Concentrations in Diabetic and Non-Diabetic Cats 
Although the differences in plasma nesfatin-1 concentrations between the lean, 
overweight, and diabetic cat groups were not statistically significant, the greatest difference in 
nesfatin-1 concentrations was found to be between diabetic and non-diabetic cats, independent of 
body condition. Median nesfatin-1 concentrations in newly diagnosed and long-term diabetic 
cats were both higher than the lean and overweight non-diabetic cats. However, the four lean 
non-diabetic cats with high nesfatin-1 concentrations created a skewed data set and impacted this 
association between diabetic and non-diabetic cats. Without these four values, a statistically 
significant difference between newly diagnosed diabetic and non-diabetic cats could be seen. 
Similarly, without these four cats, a significant relationship between plasma nesfatin-1 
concentrations and glucose (P = 0.98 with these outliers, P = 0.03 without) and fructosamine (P = 
0.96 with outliers, P = 0.01 without) was seen. This large discrepancy in significance suggests 
that there are unmeasured confounding or interacting factors in these four lean cats that influence 
nesfatin-1 concentrations. While the significance of the data without these four cats is 
questionable, it could suggest a potential association between the development of diabetes and 
increased plasma nesfatin-1 concentrations in cats. Similar results have been reported in newly 
diagnosed type 2 diabetic humans [63], and suggest that increased nesatin-1 concentrations are a 
compensatory mechanism to help maintain insulin sensitivity and peripheral glucose uptake. 
Additionally, IV nesfatin-1 injections were found to reduce blood glucose levels in 
hyperglycemic mice [45], further supporting its antihyperglycemic effects. However, given the 
limited sample size and overlap between the study groups, the results of this study should be 
interpreted with caution. Further investigation, in particular a larger sample of diabetic cats is 
required to confirm the positive correlation between diabetes and plasma nesfatin-1 
concentrations in cats.  
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3.5.4 Relationship Between Changes in Nesfatin-1 and Changes in Body weight and 
Glycemic Control Following Treatment in Newly Diagnosed Diabetic Cats 
Newly diagnosed diabetic cats showed a statistically significant decrease in plasma 
nesfatin-1 concentrations following four-weeks of diabetic treatment. This pattern reflects the 
patterns seen in human diabetics, who have decreased nesfatin-1 concentrations following 
diabetic treatment in comparison to newly diagnosed diabetic patients [63]. This could again 
reflect nesfatin-1 compensating for the insulin resistance present in newly diagnosed diabetics, as 
previously mentioned. As glycemic control, and possibly the severity of ß-cell glucose toxicity, 
improves with treatment, this compensatory mechanism abates, and plasma nesfatin-1 
concentrations decrease. 
The underlying reason for the decrease in nesfatin-1 concentrations following treatment 
in the newly diagnosed diabetic cats is uncertain as there were no statistically significant 
correlations between changes in nesfatin-1 concentrations and other variables. However, the 
changes appeared to be more related to changes in glycemic control as opposed to changes in 
body weight. Interestingly, changes in nesfatin-1 are more closely related to changes in blood 
glucose than to changes in fructosamine. This discrepancy may reflect individual variation and 
the small sample size; however, it may also be secondary to the differences in the time scale of 
the two tests. Fructosamine measures glycated protein as an indicator of average blood glucose 
levels over the previous three weeks [70], whereas blood and interstitial glucose reflects the 
current glucose levels around the time of sample collection. The effect of stress hyperglycemia 
on blood glucose concentrations was minimized by the use of the Freestyle Libre® sub-cutaneous 
glucose monitoring device and collection of blood glucose data at home in a non-stressful 
environment. Furthermore, the half-life of plasma nesfatin-1 in mice is approximately 10 minutes 
[40], and this short half-life suggests plasma nesfatin-1 may align better with measurements of 
short-term glycemic control such as blood glucose. 
Nesfatin-1 levels were not found to be closely associated with body weight or body 
condition in either diabetic or non-diabetic cats in our study. Conversely, nesfatin-1 
concentrations are reported to increase as body mass index (BMI) increases in humans [46]. 
Interestingly, the one cat that did not gain weight after four weeks of diabetic treatment also had 
the smallest decrease in plasma nesfatin-1. Altogether, these findings suggest that nesfatin-1 may 
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operate independently of body weight and adiposity in cats, and instead more closely reflect 
glycemic control in this species. Further research to confirm this is required. 
Dietary changes, as instituted in the newly diagnosed diabetic cats, may also be a 
confounding factor. In dogs, previous research has shown that high fibre/ high protein diets 
increased gastric expression of NUCB2/nesfatin-1, although concurrent plasma nesfatin-1 
concentrations were not significantly altered [30]. Given that similar dietary changes designed to 
improve glycemic control, namely increased protein content, are prescribed to diabetic cats, it is 
difficult to determine the exact impact of dietary changes alone on plasma nesfatin-1 
concentrations, if any. If diet alone has a significant impact on plasma nesfatin-1 concentrations 
and overall glycemic control, this could have implications for overweight cats and those at risk 
of developing diabetes, similar to human pre-diabetic patients where dietary modifications are 
frequently instituted as a first line treatment [12]. 
 
3.5.5 Plasma Nesfatin-1 Concentrations in Newly Diagnosed and Long-Term 
Diabetic Cats 
Patterns in plasma nesfatin-1 concentrations in newly diagnosed and long-term diabetic 
cats differed from what was expected. In a recent meta-analysis, circulating nesfatin-1 levels 
were elevated in newly diagnosed type 2 human diabetic patients but decreased in diabetic 
patients receiving anti-diabetic treatment, with the duration of anti-diabetic treatment thought to 
partially contribute to decreased nesfatin-1 concentrations [63]. This pattern was not seen in our 
study, as both newly diagnosed and long-term diabetic cats had similar, increased, plasma 
nesfatin-1 concentrations. The small sample size may have impacted our results though it is 
possible that physiological differences in cats play a role. For example, even cats who respond 
well to treatment and achieve diabetic remission have abnormal glucose metabolism [9,71]. 
Furthermore, healthy cats show blunted insulin responses to high glucose loads in comparison to 
dogs. This is thought to be related to a lack of glucokinase activity, a metabolic adaptation that is 
also found in other obligate carnivores [72]. Speculatively, these metabolic differences could 
reflect a continued need for increased nesfatin-1 secretion as a result of differences in insulin 
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secretion and function in healthy and diabetic cats, which could also suggest that cats are able to 
maintain increased nesfatin-1 secretory ability in the long term. 
Another possibility is that the diabetic treatment administered in the long-term diabetic 
cats may be less effective in comparison to human diabetic patients receiving treatment. This 
may be reflected by comparatively poorer glycemic control and therefore higher nesfatin-1 
concentrations. However, the aforementioned meta-analysis only demonstrated a relationship 
between nesfatin-1 concentrations and whether the patients had received treatment or not, an 
association was not found between nesfatin-1 concentrations and insulin resistance in human 
T2DM [63]. This suggests that whether the patient is receiving treatment is a greater determinant 
of nesfatin-1 concentrations than the efficacy of the treatment. Similarly, the long-term diabetic 
cats in our study had varying degrees of glycemic control (based on varying serum fructosamine 
concentrations) but similar nesfatin-1 concentrations. 
A major issue limiting interpretation is that we do not know the nesfatin-1 concentrations 
of the long-term diabetic cats when they were initially diagnosed. It is possible that all the long-
term diabetic cats sampled may have had even higher nesfatin-1 concentrations at diagnosis. If 
this were the case, then these values could still be consistent with what is seen in people i.e., 
nesfatin-1 concentrations are decreased with diabetic treatment. Further investigation is required 
to assess any differences that may exist between newly diagnosed and long-term diabetics, and 
the relationship between plasma nesfatin-1 and glycemic control in these patients. 
 
3.5.6 Strengths and Limitations  
To our knowledge, this is the first study to evaluate changes in plasma nesfatin-1 
concentrations in cats, particularly in relation to body condition and diabetes mellitus, and how 
nesfatin-1 concentrations change with diabetic treatment. The information in this study also 
provides a basis to further investigate the links between nesfatin-1, adiposity, and glycemic 
control and insulin resistance. However, there were several limitations. The small sample size of 
this study, particularly in the newly diagnosed diabetic cat group, made it difficult to determine 
statistically significant differences between the groups, if they do in fact exist. The sample size in 
this diabetic cat group could have been expanded to include the long-term treated diabetic cats. 
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However, given the differences in nesfatin-1 levels before and after treatment in humans [63], 
and with the changes in nesfatin-1 that occurred after treatment in our cats, it was considered that 
combining these groups would add additional variability in glycemic control and pancreatic 
function that could not be controlled for. Therefore, the long-term diabetic cats were not included 
in the statistical analysis. Another limitation is that for all cats, impaired glycemic control and 
the presence of insulin resistance was assessed indirectly and based on changes in serum glucose 
and fructosamine concentrations. Ideally, glycemic control and insulin resistance would be tested 
directly i.e., with glucose tolerance testing. However, given the logistical challenges and 
difficulties interpreting these tests in client owned cats, further investigation into the presence of 
insulin resistance in these cats was not performed. 
Changes in plasma nesfatin-1 concentrations in humans have been associated with 
hypertension, cardiac disease, and behavioural or anxiety related conditions [56,57,60]. While no 
cats in our study had a history of these conditions, or any evidence on a routine clinical exam, 
further investigations into these conditions i.e., blood pressure measurement, echocardiography, 
or thorough behavioural assessment, was not performed. Finally, the nesfatin-1 assay we used for 
our feline plasma was designed for use with rat plasma or serum. The assay showed acceptable 
performance characteristics with our feline samples, though the variations in sample recovery at 
different concentrations would limit the usefulness of this assay for diagnostic purposes. Ideally 
a feline specific nesfatin-1 assay would be used, especially if plasma nesfatin-1 was to be 
measured for diagnostic purposes. A feline specific nesfatin-1 assay is not currently available, 
though it may be prudent to re-test these samples if and when and feline specific assay becomes 
available. 
 
3.5.7 Future Studies 
There are several directions that could be taken to further investigate links between 
plasma nesfatin-1 concentrations, adiposity, and glycemic control. Given the high nesfatin-1 
concentrations seen in four individuals in the lean cat group, further investigation is indicated to 
find other factors unrelated to body condition or glycemic control that may influence nesfatin-1 
concentrations, and also whether similarly high concentrations can be seen in individual 
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overweight and diabetic cats. A prospective study over a longer time frame in overweight and 
diabetic cats would be particularly beneficial, though logistically challenging. Lean cats with 
high nesfatin-1 concentrations could also be followed over time to see if any clinically relevant 
outcomes are associated with these high nesfatin-1 concentrations. For overweight cats, serial 
plasma nesfatin-1 measurements could be taken to see if they change over time. This would be of 
particular interest if any of the overweight cats became diabetic. Plasma nesfatin-1 
concentrations could then be compared between cats that developed diabetes and those that 
didn’t, to see if changes in nesfatin-1 concentrations do truly follow apparent changes in insulin 
resistance. In the newly diagnosed diabetic cats, it may also be beneficial to follow them over a 
longer time period. This, along with a larger sample size, would hopefully allow a comparison of 
diabetic cats who do and do not achieve remission, to determine if peripheral nesfatin-1 is 
predictive of successful treatment response. Finally, it may be useful to delineate the effects 
dietary modifications alone have on plasma nesfatin-1 concentrations. This could be assessed by 
comparing nesfatin-1 concentrations in lean and overweight, non-diabetic cats before and after 
instituting dietary modifications typically prescribed to diabetic cats. 
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3.6 Conclusions 
 In conclusion, this chapter investigated plasma nesfatin-1 concentrations in cats in 
relation to body condition and diabetes mellitus, with the results suggesting changes in plasma 
nesfatin-1 concentrations may be more closely related to alterations in glycemic control/ insulin 
resistance as opposed to changes in body condition. Nesfatin-1 levels in newly diagnosed 
diabetic cats may be altered in comparison to non-diabetic cats, though a larger sample size is 
required to definitively show this relationship. There may also be as yet unknown intrinsic or 
environmental factors that increase plasma nesfatin-1 levels, particular in lean cats, and this 
possibility also requires further investigation. In diabetic cats, plasma nesfatin-1 concentrations 
significantly decrease after short-term treatment, and this decrease may be more closely related 
to changes in glycemic control rather than changes in body weight, though further investigation 
is required to determine if this relationship is significant. 
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Summary and Conclusions 
The overall goal of this thesis was to characterize tissue and plasma nesfatin-1 expression 
in cats, to better understand nesfatin-1’s relationship to adiposity and glycemic control in this 
species. Our results, in conjunction with further research, will further our understanding of how 
nesfatin-1 may be implicated in the pathophysiology of obesity and diabetes mellitus in cats. 
This has the potential to lead to the discovery of additional diagnostic or therapeutic options to 
improve management of insulin resistance and diabetes mellitus. 
The first chapter of the thesis explored the tissue mRNA expression of NUCB2/nesfatin-1, and 
how it differs between lean, overweight, and diabetic cats. Our results showed that 
NUCB2/nesfatin-1 mRNA was expressed in all tissues evaluated. mRNA expression is highest in 
the pancreas, which was a somewhat unexpected finding, and may point towards pancreatic 
nesfatin-1 having an autocrine mode of action in cats. Differences in NUCB2/nesfatin-1 
expression between study groups were most pronounced in gastric and pancreatic tissue. 
Overweight cats had marginally decreased mRNA expression, whereas diabetic cats showed a 
biphasic mode of expression, with some diabetic cats having similar expression to lean healthy 
cats, and some having comparatively decreased expression. These changes were unexpected, as 
it was hypothesized that nesfatin-1 expression would be positively correlated with insulin 
resistance as a compensatory response to maintain glycemic control. Instead, these findings 
suggest that decreased nesfatin-1 expression in some overweight and diabetic cats may reflect 
islet cell injury and a diminished capacity to maintain normoglycemia. 
The second chapter of this study explored plasma nesfatin-1 protein concentrations, and 
how they differ between lean, overweight, and diabetic cats. A rat nesfatin-1 ELISA was also 
validated for use with feline plasma. Both newly diagnosed and long-term treated diabetic cats 
had marginally increased plasma nesfatin-1 concentrations in comparison to lean and overweight 
non-diabetic cats, though these differences were not statistically significant. However, nesfatin-1 
concentrations did decrease significantly in the newly diagnosed diabetic cats following short 
term treatment, which may suggest a connection between decreasing nesfatin-1 concentrations 
and improved glycemic control. The lack of a significant difference between nesfatin-1 levels in 
lean, overweight, and diabetic cats seen in this study may be due to a sub-population of lean cats 
with unexpectedly high plasma nesfatin-1 concentrations, which may point to additional, as yet 
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unknown factors that may increase nesfatin-1 concentrations. Differences in markers of adiposity 
and metabolism i.e., BCS, body weight, and cholesterol, were not associated with differences in 
plasma nesfatin-1 concentrations.  
Interestingly, the results in plasma nesfatin-1 concentrations and NUCB2/nesfatin-1 
mRNA expression were discordant with one another. As seen in chapter one, mRNA expression 
appears to trend downwards in overweight and diabetic cats in comparison to lean cats, whereas 
plasma nesfatin-1 concentrations appear to trend upwards in comparison to lean cats. It was 
thought that nesfatin-1 tissue expression would trend in the same direction as plasma 
concentrations. However, the data suggests that difference in tissue mRNA expression may not 
reflect differences in circulating nesfatin-1 protein concentrations. This discordance has been 
seen in a study in dogs, where differences in gastric mRNA expression did not correlate to 
changes in plasma nesfatin-1 [30]. It has also been documented in a study in rats, where 
differences in pancreatic nesfatin-1 protein expression did not correlate with differences in 
circulating nesfatin-1 concentrations [66]. It is also possible that nesfatin-1 expression in other 
tissues not assessed may play a significant role in the maintenance of plasma nesfatin-1 
concentrations. These other tissues may include the liver, which plays an important role in 
compensating for the presence of insulin resistance in cats [2], and it cannot be entirely excluded 
that nesfatin-1 produced within the central nervous system has an effect on circulating nesfatin-1 
concentrations. Finally, the NUCB2/nesfatin-1 mRNA expression documented, particularly in 
the pancreas, could reflect nesfatin-1 having an autocrine mode of action. In this way, changes in 
nesfatin-1 mRNA expression may reflect local changes within the pancreas, which do not affect 
circulating nesfatin-1 concentrations.  
Future studies may involve further exploration into changes in mRNA expression in 
feline gastrointestinal tissues, in conjunction with analysis of nesfatin-1 protein expression and 
circulating nesfatin-1 levels, to obtain a more global picture of nesfatin-1 expression in cats. 
Further investigation is also indicated to see if significant differences do exist in plasma nesfatin-
1 concentrations of lean, overweight, and diabetic cats, and to identify other conditions where 
plasma nesfatin-1 concentrations are altered. Longitudinal evaluation of plasma nesfatin-1 
concentrations in cats over a longer time frame would be ideal, to further evaluate if nesfatin-1 
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concentrations change in individual cats as they develop increasing adiposity, insulin resistance, 
and eventually become clinically diabetic. 
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Appendix A: Supplemental Tables and Figures 








LC1 Stomach, Pancreas, Skeletal 
Muscle, Abdominal Adipose 
3 M Entire - 4/9 DSH 7.9 No gross lesions 
LC2 Stomach, Pancreas 
Skeletal Muscle 
3 M Entire - 4/9 DSH 6.1 No visual fat pad 
No gross lesions 
LC3 Stomach, Pancreas, Skeletal 
Muscle, Abdominal Adipose 
17 FS 3.8 5/9 DSH 7.7 Mildly increased urea 
Pancreas appeared nodular 
LC4 Stomach, Skeletal Muscle 7 MN 5.7 4/9 DMH 4.1 No abdominal adipose or pancreas 
No gross lesions 
Overweight Cats         
OC1 Stomach, Pancreas, Skeletal 
Muscle, Abdominal Adipose 
7 MN 6.97 8/9 DSH 5.3 No gross lesions identified 
Diarrhoea in colon 
OC2 Stomach, Pancreas, Skeletal 
Muscle, Abdominal Adipose 
7 MN 9.46 9/9 DSH 3.9 Mild ocular discharge 
No gross lesions identified 
OC3 Stomach, Pancreas, Skeletal 
Muscle, Abdominal Adipose 
12 MN 5.09 6/9 Siamese 7.0 Ear margins – scar tissue/ excoriations 
Dental disease. Very nodular pancreas 
with a fluid filled cyst in the right limb 
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Diabetic Cats 
DC1 Stomach, Pancreas, Skeletal 
Muscle, Abdominal Adipose 
6-8 F Entire 2.73 1/9 DMH 34 Untreated Diabetic. FeLV Positive 
Moderately increased serum urea 




Stomach, Pancreas, Skeletal 
Muscle, Abdominal Adipose 
8 MN 5.46 6/9 DSH 28.9 Treated for 3 weeks 
Diffusely nodular pancreas (small pale 
nodules), Pale liver 
DC3 Stomach, Pancreas, Skeletal 
Muscle, Abdominal Adipose 
10 FS 3.67 4/9 DSH 26.8 Untreated Diabetic 
No gross lesions 
DC4 Stomach, Pancreas, Skeletal 
Muscle, Abdominal Adipose 
7 MN 8.83 6/9 Maine 
Coon 
27.3 Uncontrolled Diabetic – Treated for 2 
months, then euthansed due to DKA 
(Ketones 5.1), increased serum urea 
Micro-abscess in the left limb of the 
pancreas, Fatty liver 
DC5 Stomach, Pancreas, Skeletal 
Muscle, Abdominal Adipose 
7 FS 4.2 4/9 Siamese 
X 
13.6 Uncontrolled Diabetic – Treated for 2-3 
months, then euthansed due to DKA 
(Ketones 5.3) 
Icteric, moderate dental disease 
Diffusely nodular pancreas 
Fatty liver 
Supplemental Table 2.1: Physical exam, necropsy, and historical findings for all cats (n = 12) enrolled for tissue collection and 
NUCB2/nesfatin-1 mRNA expression (Chapter 1). 
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Supplemental Table 2.2: Primer sequences for NUCB2/nesfatin-1 and the two reference genes, 
ß-actin and Ribosomal Protein 7 (RPS7), used for evaluating relative tissue NUCB2/nesfatin-1 




2^(-▴▴ct) Relative NUCB2/nesfatin-1 mRNA Expression 
  Stomach Pancreas Muscle Abdominal Fat 
LC1 1.21 93.05 0.86 0.62 
LC2 1.27 109.9 0.45 NA 
LC3 2.22 128.89 1.8 3.39 
LC4 0.8 NA 0.32 NA 
OC1 0.62 81.01 1.03 1.38 
OC2 1.35 28.25 0.74 2.22 
OC3 1.07 83.87 0.65 1.06 
DC1 0.51 33.36 0.4 0.71 
DC2 0.43 11.08 0.74 1.44 
DC3 1.41 147.03 0.68 0.99 
DC4 0.72 16 0.71 1.37 





Direction Sequence Amplicon Size (bp) 
NUCB2  Forward (5’ – 
3’) 
AGGCAAGAAGTGGCAAGGTT 175 
 Reverse (5’ – 
3’) 
GATCACTTGTGGCCGCTTTG 
ß-actin Forward  CGCAAGTACTCCGTGTGGAT 195 
 Reverse  TTGCCAGGGCAAACCTAGAC 
RPS7 Forward GTCCCAGAAGCCGCACTTT 74 
 Reverse CACAATCTCGCTCGGGAAAA 
Supplemental Table 2.3: Relative NUCB2/nesfatin-1 tissue expression of gastric, 
pancreatic, skeletal muscle, and abdominal fat of individual cats in comparison to average 
gastric expression from all 12 cats 
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 Measured Concentration (ng/ml) Calculated Concentration 
(ng/ml) 
Sample Recovery 
Sample 1 17.18 - - 
Sample 2 13.63 - - 
80% S1 + 20% S2 17.32 16.58 104% 
50% S1 + 50% S2 17.03 15.41 111% 
20% S1 + 80% S2 14.7 14.23 103% 
Supplemental Table 3.1: Individual modified spiked recovery test using two feline plasma 







Measured Concentration (ng/ml) Expected Concentration (ng/ml) Recovery (%) 
1:1 24.24 - - 
3:4 21.11 18.18 116 
1:2 16.35 12.12 135 
1:4 11.05 6.06 182 
1:8 5.88 3.03 194 
Supplemental Table 3.2:  Serial Dilution of Unknown Sample 1, measured concentrations 






























Measured Concentration (ng/ml) Expected Concentration (ng/ml) Recovery (%) 
1:1 20.34 - - 
3:4 18.43 15.26 121 
1:2 14.65 10.17 144 
1:4 9.22 5.09 181 
1:8 5.69 2.54 224 
Supplemental Table 3.3: Serial Dilution of Unknown Sample 2, measured concentrations under 

















Supplemental Figure 3.2: Serial Dilution of Unknown Sample 1, 3:4, 1:2, 1:4, 1:8 dilutions 
 
 
Supplemental Table 3.4: Serial Dilution of Unknown Sample 3, measured concentrations under 











Measured Concentration (ng/ml) Expected Concentration (ng/ml) Recovery (%) 
1:1 17.5 - - 
3:4 15.7 13.13 120 
1:2 11.79 8.75 135 
1:4 9.38 4.38 214 













Supplemental Figure 3.3: Serial Dilution of Unknown Sample 1, 3:4, 1:2, 1:4, 1:8 dilutions 
 
Patient Characteristics  
Group Cats were allocated into three groups according to their body condition score and 
diabetic status. The first group consists of lean, non-diabetic cats (body condition 
score 4-5/9). The second group consists of overweight, non-diabetic cats (body 
condition score 7-9/9). The third group consists of diabetic cats, of any body 
condition. 
Body Condition  Cats were allocated into two groups. Cats were defined as being lean, with a 
body condition score of less than six, and overweight, cats having a body 
condition of greater than six. One diabetic cat had a body condition score of six, 
and was placed in the overweight group 
Age Cats were allocated into three groups. Groups were defined as being less than 
five years of age, five to nine years of age, and greater than 9 years of age 
Diabetic Status Cats were allocated into two groups, categorised as being either non-diabetic or 
diabetic, regardless of body condition 
Sex Cats were sorted into two groups according to their sex (male or female) 
Supplemental Table 3.5: Definitions of categorical variables used for statistical analysis of 
plasma nesfatin-1 concentrations in lean, overweight, and newly diagnosed diabetic cats 
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Supplemental Table 3.6: Association between Plasma Nesfatin-1 and selected continuous 
variables in 13 lean, 13 overweight, and 8 newly diagnosed diabetic cats (n = 34 cats). 
 
Supplemental Table 3.7: Association between Plasma Nesfatin-1 and selected continuous 
variables in 9 lean, 13 overweight, and 8 newly diagnosed diabetic cats (n = 30 cats). The four 
highest plasma nesfatin-1 concentrations have been removed from this analysis 
 
Supplemental Table 3.8: Association between changes in weight, glucose, and fructosamine, 
independent of changes in nesfatin-1 between diabetic cats at their initial presentation and 





Variables Coefficient R-Squared 95% CI Prob > F 
Nesfatin with Fructosamine -0.01 0.0001 -0.5 – 0.47 0.96 
Nesfatin with Cholesterol 0.01 0.01 -0.29 – 0.06 0.51 
Nesfatin with Weight -0.3 0.08 -0.54 – 0.06 0.1 
Nesfatin with Glucose -0.01 0.00 -0.7 – 0.68 0.98 
Variables Coefficient R-Squared 95% CI Prob > F 
Nesfatin with Fructosamine 0.27 0.22 0.07 – 0.46 0.01 
Nesfatin with Cholesterol 0.06 0.04 -0.05 – 0.16 0.28 
Nesfatin with Weight -0.07 0.02 -0.24 – 0.11 0.44 
Nesfatin with Glucose 0.32 0.15 0.03 – 0.61 0.03 
Variables Coefficient R-Squared 95% CI Prob > F 
Weight with Glucose 0.20 0.30 -0.10 – 0.50 0.16 
Weight with Fructosamine 0.38 0.92 0.25 – 0.52 <0.01 








Supplemental Table 3.9: Multivariate model assessing changes in glucose in relation to changes 
in plasma nesfatin-1 in diabetic cats at their initial presentation and following four weeks of 




Multivariate Regression Model R2 P > F 
0.59 0.17 
Variables Prob >F Coefficient 95% CI 
Glucose 0.14 0.59 -1.5 – 0.3 
Fructosamine 0.93 0.03 -0.91 – 0.85 
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Appendix B: Owner Consent and Enrolment Forms 
Consent Form For Animal Owners – Nesfatin-1 in Lean and Obese Healthy Cats 
You have been invited to enter __________________ (pet’s name) in a research project entitled 
“Evaluation of nesfatin-1 in lean, obese and diabetic cats”. Please read this form carefully, 
and feel free to ask questions you might have.  
Researcher(s):  
Dr. Melissa Meachem: Department of Veterinary Pathology, Western College of Veterinary 
Medicine (WCVM). Primary Investigator; melissa.meachem@usask.ca, 306-966-2688 
Dr. Peter Toh: Graduate Student, Department of Veterinary Pathology, Western College of 
Veterinary Medicine. Co-Primary Investigator; peter.toh@usask.ca, 306-966-7309 
Dr. Elizabeth Snead: Small Animal Clinical Sciences, Western College of Veterinary Medicine 
(WCVM); liz.snead@usask.ca, 306-966-7068 
Dr. Chantal McMillan: Department of Clinical and Diagnostic Sciences, University of Calgary 
Faculty of Veterinary Medicine, +1 (403) 210-6002 
 
Funding Source(s): Companion Animal Health Fund, Western College of Veterinary Medicine  
Purpose and Objective of the Study:   
Similar to humans, there has been a major increase in the incidence of diabetes in pet cats, which 
is often associated with obesity related changes in insulin sensitivity. Management of these cats 
could be greatly improved if we could more accurately predict and monitor how individual cats 
will respond to treatment, or even identify a ‘pre-diabetic state,’ in which cats have some degree 
of insulin resistance but are not yet clinically diabetic. At this point in time, there are no tests 
available to accomplish this. Nesfatin-1 is a recently discovered hormone that plays a role in 
regulating food intake, blood sugar and insulin levels. Studies in humans have shown that 
increases in nesfatin-1 are correlated with other signs of insulin resistance in obese and diabetic 
people, and that nesfatin-1 levels decrease following treatment of type 2 diabetes.  
Description of the Procedures: If your pet participates in this study, we will ask you a few 
questions about their medical history. Your pet will have a physical exam, and a single small 
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blood and urine sample will also be taken to look at a few health parameters in addition to 
nesfatin-1 levels. The urine sample will be collected by placing a needle through the abdominal 
wall into the urinary bladder (cystocentesis) using ultrasound guidance. The method of blood and 
urine collection will be performed according to routine VMC guidelines, and are standard 
procedures for collecting blood and urine samples in small animal patients. However, we will be 
collecting a slightly larger blood sample than routine for the purposes of our study. The blood 
and urine sampling should take about 30 minutes and will take place at the Veterinary Medical 
Centre.  
Knowledge Transfer: The results of this study will be analyzed and reported in a manuscript 
with the goal of being published in a scientific journal.  Results of blood work to assess general 
health will be communicated to you. 
Potential Benefits: Diabetes mellitus is a common disease in cats that requires both financial 
and time commitments from owners. This study aims to provide new information that will not 
only help us to further understand the development of this condition, but also potentially help 
identify at risk individuals.  In addition, by choosing to participate, your cat will receive a free 
physical exam by a veterinarian, as well as blood and urine work that will allow you to have 
greater knowledge of your cat’s overall health.  
Potential Risks and Discomforts: While small, there is a risk of your pet developing bruising at 
the site of the blood collection. Cystocentesis to collect a urine sample is a quick and simple 
procedure and risks will be minimized by use of ultrasound guidance to locate the bladder. All 
researchers are experienced at blood and urine collection and will be using appropriate 
techniques and materials to minimize these risks.  
Financial Implications: There will be no cost to you for entering your animal(s) in this study. 
You will not be charged for any of the procedures performed solely for the study’s purposes, 
including blood work and urinalysis to assess general health.  
Confidentiality: While absolute confidentiality cannot be guaranteed, every effort will be made 
to ensure that the information collected for this study is kept entirely confidential. Each cat will 
be deidentified with an alphanumeric code for the purpose of the study. Your name or that of 
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your animal(s) will not be attached to any information nor mentioned in any study report, nor be 
made available to anyone except the research team. Results of this study are intended for 
publication in scientific journals and presentation at related conferences and workshops, but your 
identity or that of your animal(s) will not be revealed.  
Data Storage: All research materials will be stored in a secured location under lock- and-key 
for a period of 5 years post publication minimum as per the U of S Responsible Conduct of 
Research Policy, see: http://www.usask.ca/university_secretary/policies/research/8_25.php).  
Voluntary Participation: Your animal’s participation is voluntary, and you may withdraw your 
animal(s) from the research project for any reason, at any time, without penalty of any sort. If 
you do not wish to participate, you do not have to provide any reason for your decision, nor will 
you lose the benefit of any veterinary care your animal(s) is receiving. If you withdraw your 
animal(s) from the research project any data collected about him or her during their enrollment in 
the study will be retained for analysis.  
Questions: If you have any questions concerning the research project, please feel free to ask at 
any point; you can contact the primary investigators (Dr. Meachem or Dr. Toh) by phone or e-
mail using the contact details listed above. This research project has been approved on ethical 
grounds by the University of Saskatchewan Animal Research Ethics Board. Any questions 
regarding the ethical conduct of this research may be addressed to that committee through the 









Consent to Participate: Please read and initial the following statements to signify your 
agreement and sign below.  
______ I have read or have had the consent form read to me and I understand the consent form.  
______ I have had an opportunity to ask questions and my/our questions have been answered.  
______ I freely consent to entering my animal(s) in this study.  
______ I have been told that a signed and dated copy of this Consent Form will be given to me 
for my records.  
______ I am at least 18 years of age and am the legal owner of the animal(s) or am authorized to 
make decisions regarding this(these) animal(s) on the owner’s behalf. 
 
_________________________________________ Signature of Owner or Agent  
 
____________________ Date  
 
_________________________________Signature of Individual conducting the Consent Process  
 
____________________ Date  
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Consent Form For Animal Owners – Feline Diabetics 
You have been invited to enter ___________________(pet’s name) in a research project entitled 
“Evaluation of nesfatin-1 in lean, obese and diabetic cats”. Please read this form carefully, 
and feel free to ask questions you might have.  
Researcher(s):  
Dr. Melissa Meachem: Department of Veterinary Pathology, Western College of Veterinary 
Medicine (WCVM). Primary Investigator; melissa.meachem@usask.ca, 306-966-2688 
Dr. Peter Toh: Graduate Student, Department of Veterinary Pathology, Western College of 
Veterinary Medicine. Co-Primary Investigator; peter.toh@usask.ca, 306-966-7309 
Dr. Elisabeth Snead: Small Animal Clinical Sciences, Western College of Veterinary Medicine 
(WCVM); liz.snead@usask.ca, 306-966-7068 
Dr. Chantal McMillan: Department of Clinical and Diagnostic Sciences, University of Calgary 
Faculty of Veterinary Medicine, +1 (403) 210-6002 
 
Funding Source(s):  
Companion Animal Health Fund, Western College of Veterinary Medicine  
Purpose and Objective of the Study:   
Similar to humans, there has been a major increase in the incidence of diabetes in pet cats, which 
is often associated with obesity related changes in insulin sensitivity and insulin function. 
Management of these cats could be greatly improved if we could more accurately predict and 
monitor how individual cats will respond to treatment. At this point in time, there are no tests 
available to accomplish this. Nesfatin-1 is a recently discovered hormone that plays a role in 
regulating food intake, blood sugar and insulin levels. Studies in humans have shown that 
increases in nesfatin-1 are correlated with other signs of insulin resistance in obese and diabetic 
people, and that nesfatin-1 levels decrease with treatment of type 2 diabetes. Recent research has 
shown that nesfatin-1 can be measured in cats using a commercially available assay. Given feline 
diabetes shares many similarities with type 2 diabetes in humans, we predict that nesfatin-1 will 
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have similar effects and will be a useful marker in predicting or monitoring response to 
treatment. 
Description of the Procedures: If your pet participates in this study, we will ask you a few 
questions about their medical history. Your pet will have a physical exam and a blood and urine 
sample will also be taken to look at a few health parameters and at nesfatin-1 levels, prior to 
starting diabetic treatment.  
The urine sample will be collected by placing a needle through the abdominal wall into the 
urinary bladder (cystocentesis) using ultrasound guidance. The blood and urine sampling should 
take about 30 minutes and will take place at the Veterinary Medical Centre. The method of blood 
and urine collection will be performed according to routine VMC guidelines and are standard 
procedures for collecting blood and urine samples in small animal patients. However, we will be 
collecting a slightly larger blood sample than routine for the purposes of our study. 
Following the initial blood work, your cat will begin diabetic treatment (insulin injections and a 
low carbohydrate diet), and additional blood work will be taken at 4 weeks into their treatment, 
to assess nesfatin-1 levels and a few other health parameters. At this appointment, your cat will 
also have glucose monitoring device placed, which will be attached to skin on the backs of their 
neck. The devices will stay in place for up to 14 days at a time, and you will be given a device to 
record the results electronically, you will need to record the results using the device at least every 
8 hours. Overall you will be required to attend 2 appointment 4 weeks apart, both of which will 
take around 30-40 minutes each, and you will also be required to measure blood glucose readings 
at home electronically for up to 14 days after placement of the monitoring device. 
Knowledge Transfer: The results of this study will be analyzed and reported in a manuscript 
with the goal of being published in a scientific journal. Results of blood work to assess general 
health parameters and information derived from an implanted blood glucose device will be 
communicated to you.  
Potential Benefits: Diabetes mellitus is a common disease in cats that requires both financial 
and time commitments from owners. This study aims to provide new information that will not 
only help understand the development of this condition, but also potentially help identify at risk 
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individuals.  In addition, by choosing to participate, your cat will receive a free physical exam by 
veterinarians, blood work and urinalysis that will assess their general health, a device that allows 
monitoring of blood glucose at home, and food specially formulated for diabetic cats. This will 
enable you to understand more about the overall health of your cat, as well as ensuring your cat 
is receiving optimal management for the diabetes. 
Potential Risks and Discomforts: While small, there is a risk of your pet developing bruising at 
the site of the blood collection. Cystocentesis to collect a urine sample is a quick and simple 
procedure and risks will be minimized by use of ultrasound guidance to locate the bladder. All 
researchers are experienced at blood and urine collection and will be using appropriate 
techniques and materials to minimize these risks. After placement of the glucose monitoring 
device, your cat will also be required to wear a soft protective collar while it is attached 
Financial Implications: There will be no cost to you for entering your animal(s) in this study. 
You will not be charged for any of the procedures performed solely for the study’s purposes. 
You will be reimbursed for the initial blood work, and the blood work at the scheduled re-check 
appointment 4 weeks later. There is no cost associated with use of the blood glucose 
measuring device, and at both appointments you will receive dry food and/or canned food 
(sufficient for 4 weeks) courtesy of Purina®. If unforeseen circumstances arise and your cat 
passes away or is withdrawn from the study, you will be reimbursed for the blood work 
during the time which your cat was part of the study. All unrelated or additional costs for 
diagnosis, management and treatment of your animal(s) outside of these scheduled appointments 
are your responsibility. You will receive no additional financial reimbursement for entering your 
animal(s) in this study.  
Confidentiality: While absolute confidentiality cannot be guaranteed, every effort will be made 
to ensure that the information collected for this study is kept entirely confidential. Each cat will 
be deidentified with an alphanumeric code for the purpose of the study. Your name or that of 
your animal(s) will not be attached to any information nor mentioned in any study report, nor be 
made available to anyone except the research team. Results of this study are intended for 
publication in scientific journals and presentation at related conferences and workshops, but your 
identity or that of your animal(s) will not be revealed.  
 100 
Data Storage: All research materials will be stored in a secured location under lock- and-key 
for a period of 5 years post publication minimum as per the U of S Responsible Conduct of 
Research Policy, see: http://www.usask.ca/university_secretary/policies/research/8_25.php).  
Voluntary Participation: Your animal’s participation is voluntary, and you may withdraw your 
animal(s) from the research project for any reason, at any time, without penalty of any sort. If 
you do not wish to participate, you do not have to provide any reason for your decision, nor will 
you lose the benefit of any veterinary care your animal(s) is receiving. If you withdraw your 
animal(s) from the research project any data collected about him or her during their enrollment in 
the study will be retained for analysis.  
Questions: If you have any questions concerning the study protocol, please feel free to ask at 
any point; you can contact the primary investigators (Dr. Meachem or Dr. Toh). If you have 
concerns about the health of your cat, or questions regarding the management of your 
diabetic cat during the study, then you can contact Dr. Snead. Please use the phone numbers 
or e-mail addresses provided above. This research project has been approved on ethical grounds 
by the University of Saskatchewan Animal Research Ethics Board. Any questions regarding the 
ethical conduct of this research may be addressed to that committee through the Research Ethics 










Consent to Participate: Please read and initial the following statements to signify your 
agreement and sign below.  
______ I have read or have had the consent form read to me and I understand the consent form.  
______ I have had an opportunity to ask questions and my/our questions have been answered.  
______ I freely consent to entering my animal(s) in this study.  
______ I have been told that a signed and dated copy of this Consent Form will be given to me 
for my records.  
______ I am at least 18 years of age and am the legal owner of the animal(s) or am authorized to 
make decisions regarding this(these) animal(s) on the owner’s behalf. 
 




_________________________________Signature of Individual conducting the Consent Process  
 






Consent Form for Animal Owners – Nesfatin-1 in Long Term Diabetic Cats 
You have been invited to enter __________________ (pet’s name) in a research project entitled 
“Evaluation of nesfatin-1 in lean, obese and diabetic cats”. Please read this form carefully, 
and feel free to ask questions you might have. 
Researcher(s): 
Dr. Melissa Meachem: Department of Veterinary Pathology, Western College of Veterinary 
Medicine (WCVM). Primary Investigator; melissa.meachem@usask.ca, 306-966-2688 
Dr. Peter Toh: Graduate Student, Department of Veterinary Pathology, Western College of 
Veterinary Medicine. Co-Primary Investigator; peter.toh@usask.ca, 306-966-7309 
Dr. Elisabeth Snead: Small Animal Clinical Sciences, Western College of Veterinary Medicine 
(WCVM); liz.snead@usask.ca 306-966-7068 
Dr. Chantal McMillan: Department of Clinical and Diagnostic Sciences, University of Calgary 
Faculty of Veterinary Medicine, +1 (403) 210-6002 
Funding Source(s): 
Companion Animal Health Fund, Western College of Veterinary Medicine 
Purpose and Objective of the Study: 
Similar to humans, there has been a major increase in the incidence of diabetes in pet cats, which 
is often associated with obesity related changes in insulin sensitivity. Management of these cats 
could be greatly improved if we could more accurately predict and monitor how individual cats 
will respond to treatment, or even identify a ‘pre-diabetic state,’ in which cats have some degree 
of insulin resistance but are not yet clinically diabetic. At this point in time, there are no tests 
available to accomplish this. Nesfatin-1 is a recently discovered hormone that plays a role in 
regulating food intake, blood sugar and insulin levels. Studies in humans have shown that 
increases in nesfatin-1 are correlated with other signs of insulin resistance in obese and diabetic 
people, and that nesfatin-1 levels decrease following successful treatment of type 2 diabetes. 
 103 
Description of the Procedures: If your pet participates in this study, we will ask you a few 
questions about their medical history. Your pet will have a physical exam, and a single small 
blood and urine sample will also be taken to look at a few health parameters in addition to 
nesfatin-1 levels. The urine sample will be collected by placing a needle through the abdominal 
wall into the urinary bladder (cystocentesis) using ultrasound guidance. The method of blood and 
urine collection will be performed according to routine VMC guidelines and are standard 
procedures for collecting blood and urine samples in small animal patients. However, we will be 
collecting a slightly larger blood sample than routine for the purposes of our study. The blood 
and urine sampling should take about 30 minutes and will take place at the Veterinary Medical 
Centre. 
Knowledge Transfer: The results of this study will be analyzed and reported in a manuscript 
with the goal of being published in a scientific journal. Results of blood work to assess general 
health will be communicated to you. 
Potential Benefits: Diabetes mellitus is a common disease in cats that requires both financial 
and time commitments from owners. This study aims to provide new information that will not 
only help us to further understand the development of this condition, but also potentially help 
identify at risk individuals. In addition, by choosing to participate, your cat will receive a free 
physical exam by a veterinarian, as well as blood and urine work that will allow you to have 
greater knowledge of your cat’s overall health. 
Potential Risks and Discomforts: While small, there is a risk of your pet developing bruising at 
the site of the blood collection. Cystocentesis to collect a urine sample is a quick and simple 
procedure and risks will be minimized by use of ultrasound guidance to locate the bladder. All 
researchers are experienced at blood and urine collection and will be using appropriate 
techniques and materials to minimize these risks. 
Financial Implications: There will be no cost to you for entering your animal(s) in this study. 
You will not be charged for any of the procedures performed solely for the study’s purposes, 
including blood work and urinalysis to assess general health. 
Confidentiality: While absolute confidentiality cannot be guaranteed, every effort will be made 
to ensure that the information collected for this study is kept entirely confidential. Each cat will 
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be deidentified with an alphanumeric code for the purpose of the study. Your name or that of 
your animal(s) will not be attached to any information nor mentioned in any study report, nor be 
made available to anyone except the research team. Results of this study are intended for 
publication in scientific journals and presentation at related conferences and workshops, but your 
identity or that of your animal(s) will not be revealed. 
Data Storage: All research materials will be stored in a secured location under lock- and-key for 
a period of 5 years post publication minimum as per the U of S Responsible Conduct of Research 
Policy, see: http://www.usask.ca/university_secretary/policies/research/8_25.php). 
Voluntary Participation: Your animal’s participation is voluntary, and you may withdraw your 
animal(s) from the research project for any reason, at any time, without penalty of any sort. If 
you do not wish to participate, you do not have to provide any reason for your decision, nor will 
you lose the benefit of any veterinary care your animal(s) is receiving. If you withdraw your 
animal(s) from the research project any data collected about him or her during their enrollment in 
the study will be retained for analysis. 
Questions: If you have any questions concerning the research project, please feel free to ask at 
any point; you can contact the primary investigators (Dr. Meachem or Dr. Toh) by phone or e-
mail using the contact details listed above. This research project has been approved on ethical 
grounds by the University of Saskatchewan Animal Research Ethics Board. Any questions 
regarding the ethical conduct of this research may be addressed to that committee through the 








Consent to Participate: Please read and initial the following statements to signify your 
agreement and sign below. 
 
______ I have read or have had the consent form read to me and I understand the consent form. 
______ I have had an opportunity to ask questions and my/our questions have been answered. 
______ I freely consent to entering my animal(s) in this study. 
______ I have been told that a signed and dated copy of this Consent Form will be given to me 
for my records. 
 
______ I am at least 18 years of age and am the legal owner of the animal(s) or am authorized to 
make decisions regarding this(these) animal(s) on the owner’s behalf. 
 
_________________________________________ Signature of Owner or Agent 
____________________ Date 









Consent Form For Animal Owners – Nesfatin-1 Tissue Study 
You have been invited to enter __________________ (pet’s name) in a research project entitled 
“Evaluation of nesfatin-1 in lean, obese and diabetic cats”. Please read this form carefully, 
and ask questions you might have.  
Researcher(s):  
Dr. Melissa Meachem: Department of Veterinary Pathology, Western College of Veterinary 
Medicine (WCVM). Primary Investigator; melissa.meachem@usask.ca, 306-966-2688 
Dr. Peter Toh: Graduate Student, Department of Veterinary Pathology, Western College of 
Veterinary Medicine. Co-Primary Investigator; peter.toh@usask.ca, 306-966-7309 
Dr. Elisabeth Snead: Small Animal Clinical Sciences, Western College of Veterinary Medicine 
(WCVM); liz.snead@usask.ca 306-966-7068 
Dr. Chantal McMillan: Department of Clinical and Diagnostic Sciences, University of Calgary 
Faculty of Veterinary Medicine, +1 (403) 210-6002 
 
Funding Source(s): Companion Animal Health Fund, Western College of Veterinary Medicine  
Purpose and Objective of the Study:   
Similar to humans, there has been a major increase in the incidence of diabetes in pet cats, which 
is often associated with obesity related changes in insulin sensitivity. Nesfatin-1 is a recently 
discovered hormone that plays a role in regulating food intake, blood sugar and insulin levels.  
Studies in humans have shown that increases in nesfatin-1 are correlated with other signs of 
insulin resistance in obese and diabetic people, and we are investigating if similar changes occur 
in cats. Little is currently known about the tissue expression of this new hormone throughout the 
gastrointestinal system, and how that may change with obesity and diabetes in cats. Investigating 
how the expression of nesfatin-1 changes may help us understand how diabetes develops in cats, 
and assist in the development new ways of monitoring and/or predicting cats that are at risk of 
developing diabetes. 
Description of the Procedures: Restraint and humane euthanasia will be performed by trained 
personel according to hospital guidelines, via the placement of an intravenous catheter and 
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administration of pentobarbital sodium. Gentle handling techniques will be used at all time to 
minimize stress and discomfort. A blood sample will be collected if recent blood work has not 
been performed, this will be collected via the catheter already placed for euthanasia. After 
euthanasia has been confirmed, small pieces of tissue (stomach, pancreas, skeletal muscle and 
abdominal fat) will be collected via an abdominal incision using surgical instruments. After this 
has been completed your cat will be released back to you for burial/ cremation as previously 
arranged with the attending veterinarian. 
Knowledge Transfer: The results of this study will be analyzed and reported in a manuscript 
with the goal of being published in a scientific journal. 
Potential Benefits: Diabetes mellitus is a common disease in cats that requires both financial 
and time commitments from owners. This study aims to provide new information that will help 
us to further understand the development of this condition. 
Potential Risks and Discomforts: Slight discomfort may be felt during placement of the 
intravenous catheter, and sedation may be administered if any distress/ discomfort is apparent. 
Financial Implications: There will be no cost to you for entering your animal(s) in this study.  
Confidentiality: While absolute confidentiality cannot be guaranteed, every effort will be made 
to ensure that the information collected for this study is kept entirely confidential. Each cat will 
be deidentified with an alphanumeric code for the purpose of the study. Your name or that of 
your animal(s) will not be attached to any information nor mentioned in any study report, nor be 
made available to anyone except the research team. Results of this study are intended for 
publication in scientific journals and presentation at related conferences and workshops, but your 
identity or that of your animal(s) will not be revealed.  
Data Storage: All research materials will be stored in a secured location under lock- and-key 
for a period of 5 years post publication minimum as per the U of S Responsible Conduct of 
Research Policy, see: http://www.usask.ca/university_secretary/policies/research/8_25.php).  
Voluntary Participation: Your animal’s participation is voluntary, and you may withdraw your 
animal(s) from the research project for any reason, at any time, without penalty of any sort.  
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Questions: If you have any questions concerning the research project, please feel free to ask at 
any point; you can contact the primary investigators by phone or e-mail using the contact details 
listed above. This research project has been approved on ethical grounds by the University of 
Saskatchewan Animal Research Ethics Board. Any questions regarding the ethical conduct of 
this research may be addressed to that committee through the Research Ethics Office (306-966- 


















Consent to Participate: Please read and initial the following statements to signify your 
agreement and sign below.  
______ I have read or have had the consent form read to me and I understand the consent form.  
______ I have had an opportunity to ask questions and my/our questions have been answered.  
______ I freely consent to entering my animal(s) in this study.  
______ I have been told a signed and dated copy of this Consent Form will be given to me for 
my records.  
______ I am at least 18 years of age and am the legal owner of the animal(s) or am authorized to 
make decisions regarding this(these) animal(s) on the owner’s behalf. 
 
_________________________________________ Signature of Owner or Agent  
 
____________________ Date  
 
________________________________ Signature of Individual conducting the Consent Process  
 
____________________ Date  
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Appendix C: Study Protocols 
RNEasy Tissue Prepration & RNA Extraction Protocol – Stomach and Pancreas 
Materials Needed Before Starting (all labelled) 
- 2x RINO RNA Lysis Tubes 
- 2x RNEasy Columns 
- 2x 1.7ml Eppendorf Tubes 
- 2x 2ml Tubes (Supplied with kit) 
- 2x 1.5ml Tubes (Supplied with kit) 
- 2x 1.7ml Eppendorf tubes (empty, for balancing in centrifuge) 
 
Perform extractions on 2 tissues at a time 
Initial Tissue Preparation 
- Place three petri dishes in -20 freezer for at least 10 minutes to cool down 
- Take tissue out of -80 one at a time 
- For Each tissue 
o Cut a small slice of tissue off, and put it in one of the -20 petri dishes 
 Put tissue straight back in the -80 Freezer 
o Repeat for the other tissue 
o Cut small pieces of tissue off the original slice 
 For Pancreas and Stomach: Cut off 10-20mg tissue with 300uL buffer 
- Place tissue in RINO RNA Lysis Tube with 300ul Buffer RLT + ß-ME 
o Put both tubes into bullet blender for the following times 






- Spin RINO RNA Lysis tube again in regular centrifuge, 3 minutes at max speed 
- Add equivalent volume of 70% Ethanol (350ul), mix by pipetting 
- Extract supernatant, place it into new 1.7ml Eppendorf 
o For pancreas and stomach: Put 250uL of sample in tube with ethanol 
 Add extra 100uL of buffer RLT 
- Transfer up to 700ul (i.e. the whole sample) into the RNEasy spin column 
o Centrifuge 15-30s at >10,000rpm/ 8000g – Discard flow-through 
- Add 700ul Buffer RW1 to spin column 
o Centrifuge 15-30s >10,000rpm – Discard flow through 
- Add 500ul Buffer RPE to column 
o Centrifuge 15-30s >10,000rpm – Discard flow through 
- Add 500ul Buffer RPE to column 
o Centrifuge 2 minutes >10,000 – Place column into supplied new 2ml tube 
- Centrifuge column 1 minute @ full speed 
- Place column in a supplied 1.5ml column 
o For All Tissues: Add 50uL RNAse free water 
- Centrifuge Column for 1 minute at >10,000rpm/ full speed 
 
Measure concentration/ absorbance ratio on Nanodrop 
- Zero machine with water twice, then add sample 
o Re-Zero with Water between analysis 
o Check concentration, 260/230 and 260/280 ratio 
- Then dilute RNA to 50ng/ul (as using 2ul of sample in each well) 
o Make 2 dilutions, each 100ul 
o DNAse treat one sample and freeze in 50uL aliquots 
o Re-check DNAse treated sample on Nanodrop 
o Freeze one 100ul sample untreated as a backup 
 And freeze remainder of undiluted sample (if still some leftover) 
TRIzol RNA Extraction Protocol – For Muscle and Fat 
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Tubes Required for each set of 2 tissues 
- 2 x RINO RNA Lysis Tubes 
- 6 x 1.7ml Eppendorf Tubes 
- 2 x spin columns 2 x extra collection tubes 2 x recovery tubes 
 
Tissue Extraction 
- Put 600ul of Trizol reagent into a labelled RINO tube 
- Fat: 2-3 thin slices of tissue cut in the -20 freezer 
- Muscle: 1-2 thin slices of tissue cut in the -20 freezer 
- Add tissue into RINO tube with TRIzol 
- Homogenize Tissue: Bullet Blender Setting – Speed 10 for 4 Minutes 
 
RNA Processing  
1. Place 600ul of the homogenized samples into a new Eppendorf tube 
a. Must take it out of the RINO tube before centrifuging 
2. Centrifuge sample for 5 minutes at max speed 
3. Transfer 400ul of the supernatant (avoid fat/tissue sediment) into new Eppendorf tube 
4. Incubate for 5 minutes at room temperature 
5. Add 80uL of chloroform (or 20ul of chloroform per 100ul of supernatant), mix gently 
then incubate for another 2-3 minutes 
6. Centrifuge sample for 15 minutes at max speed 
7. Transfer 200-250uL of sample into a new Eppendorf tube 
a. Make sure you only take the top layer and don’t touch the interphase layer 
8. Add 200-250ul of ethanol and vortex to mix 
 
Binding the RNA to the Membrane and Washing the Membrane 
9. Transfer Trizol/ Ethanol sample into a spin cartridge 
10. Centrifuge at max speed for 20 seconds, discard flow through 
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11. Add 700ul of wash buffer I 
12. Centrifuge max speed for 20 seconds, discard flow through 
13. Put spin column into a new collection tube 
14. Add 500ul wash buffer II 
15. Centrifuge max speed for 20 seconds, discard flow through 
16. Add 500ul wash buffer II 
17. Centrifuge max speed for 20 seconds, discard flow through 
 
Eluting the RNA 
18. Centrifuge at max speed for 1 minute to dry the membrane 
19. Insert spin cartridge into a collection tube 
20. Add 100ul RNA free water to the centre of the spin cartridge 
21. Incubate for 1 minute 
22. Centrifuge at max speed for 2 minutes 
 
Measure concentration/ absorbance ratio on Nanodrop 
- Zero machine with water twice, then add sample 
o Re-Zero with Water between analysis 
o Check concentration, 260/230 and 260/280 ratio 
- Then dilute RNA to 50ng/ul (as using 2ul of sample in each well) 
o Make 2 dilutions, each 100ul 
o DNAse treat one sample and freeze in 50uL aliquots 
o Re-check DNAse treated sample on Nanodrop 
o Freeze one 100ul sample untreated as a backup 
 And freeze remainder of undiluted sample (if still some leftover) 
 
DNAse Digestion Protocol (After initial RNA extraction and nanodrop measurement) 
Turn on water bath and set at 37C  
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- DNAse I Buffer and DNAse Inactivation Reagent need to be defrosted 
- rDNAse I does not need defrosting 
 
For 50uL of Sample (<200ng/uL RNA) 
1. Add 5uL DNAse I Buffer (0.1 volume) + 1uL rDNAse I and mix gently (e.g. touch on 
the vortex) 
2. Incubate at 37C for 20-30 minutes 
3. Add 5uL resuspended DNAse Inactivation Reagent (0.1 volume) 
a. Vortex sample before use 
4. Incubate at room temperature for 2 minutes 
a. Vortex 2-3 times during this time to ensure proper mixing 
5. Centrifuge >12,500rpm for 1.5 minutes 
a. Place supernatant in new tube 
 
For 100uL of Sample (<200ng/uL RNA) 
1. Add 10uL DNAse I Buffer (0.1 volume) + 1uL rDNAse I and mix gently (e.g. touch on 
the vortex) 
2. Incubate at 37C for 20-30 minutes 
3. Add 10uL resuspended DNAse Inactivation Reagent (0.1 volume) 
a. Vortex sample before use 
4. Incubate at room temperature for 2 minutes 
a. Vortex 2-3 times during this time to ensure proper mixing 
5. Centrifuge >12,500rpm for 1.5 minutes 
a. Place supernatant in new tube 
Note: DNAse Inactivation Reagent can become fluid depleted and difficult to pipette with 
multiple uses. If it dries out add approx. 20-25% bed volume of the remaining reagent 
o E.g. approx 300uL reagent, add 60uL water 
Gel Electrophoresis – Protocol 
For Small Gel (8 wells) 
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- Get gel mold and casting tray, use balance to ensure a flat surface 
o Firmly fix mold into the casting tray 
- Measure out 50ml TBE buffer and into conical flask 
- Measure out 0.5-0.55g agarose and place into flask 
- Place paper towel on microwave and put flask on top 
- Microwave for 2 x 30 second bursts, swirling/ mixing in between 
o And then an extra 10-15 seconds 
o Mixture should be completely clear 
- Allow to cool slightly for 5-10 minutes 
- Add 2ul ethidium bromide and swirl to mix 
- Pour into prepared mold/ casting tray 
- Place comb into gel and put aside to set 
 
For Medium Gel (20 wells) 
- Get gel mold and casting tray, use balance to ensure a flat surface 
o Firmly fix mold into the casting tray 
- Measure out 100ml TBE buffer and into conical flask 
- Measure out 1-1.05g agarose and place into flask 
- Place paper towel on microwave and put flask on top 
- Microwave for 3 x 30 second bursts, swirling/ mixing in between 
o And then an extra 10-15 seconds 
o Mixture should be completely clear 
- Allow to cool slightly for 5-10 minutes 
- Add 4ul ethidium bromide and swirl to mix 
- Pour into prepared mold/ casting tray 




- Wells should be close to the negative terminal (product runs to positive terminal) 
- Place gel into station – If needed add TBE buffer to ensure gel is covered 
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- Place DNA ladder into well 
o If running extracted RNA – 10ul 
o If running PCR product – 8ul 
- Fill wells with each product – mix samples on wax paper before loading 
o If running extracted RNA – 8ul sample + 2ul loading dye 
 Run at 55V for 70-80 minutes 
o If running PCR product – 5ul sample + 2ul loading dye 















One-Step PCR Protocol 
For All Tissues 
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Ingredients for 1 reaction 
- 12.5ul Master Mix 
- 2ul F Primer (1:10 dilution) 
- 2ul R Primer (1:10 dilution) 
- 0.25ml RT mix 
- 2ul Template/ water (or enough to make up 100ng RNA) 
- 6.25ul RNAse free water (or less if more template required) 
 
Ingredients for 1 Minus-RT Control reaction 
- 12.5ul Master Mix 
- 2ul F Primer (1:10 dilution) 
- 2ul R Primer (1:10 dilution) 
- 2ul Template (or enough to make up 100ng RNA) 
- 6.5ul RNAse free water (or less if more template required) 
 
Reactions Required Per Sample – TWO samples at a time 
- Each Primer Pair in Triplicate – 9 Samples total 
- NTCs in triplicate – 9 Samples 
o Assessing two samples, only need to do NTCs once 
- Minus-RT Control in triplicate – 9 Samples 
o Need to do twice (one for each sample, assessing gDNA contamination in each) 
 
Mix Required for NTCs + Sample 1 + Sample 2 In Triplicate 
- Total of 9 Mixes for Each Primer Pair (27 reactions total) – So Mix up 10 reactions 
 
Mix Required for -RT Controls – Sample 1 and Sample 2 in Triplicate 




- UV light treat tube strips 20 minutes before filling (while preparing master mix) 
- Take water for NTCs from the PCR water from the One-Step Kit (25uL at a time) 
- Add 1 extra reaction amount per 10 reactions for each primer pair 
o Allowing for wastage during pipetting 
All Tissues – 2 Tissues at a time 
Ingredients for 10 reactions 
- 125ul Master Mix 
- 20ul F Primer (1:10 dilution) 
- 20ul R Primer (1:10 dilution) 
- 2.5ml RT mix 
- 62.5ul RNAse free water (or less if more template required) 
- 2ul Template/ water per well 
 
Ingredients for 7 Minus-RT Control reaction 
- 87.5ul Master Mix 
- 14ul F Primer (1:10 dilution) 
- 14ul R Primer (1:10 dilution) 
- 45.5ul RNAse free water 
- 2ul Template per well 
 
Mix Master Mix + RT Mix + Primer + Water in the PCR Room 
Add RNA Template/ water control in the clean box outside the room 
PCR Parameters 
- 10 minutes annealing @ 50C 
- 5 minutes activation @ 95C 
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- 35 Cycles 
o 10 seconds @ 95 30 seconds @ 60 10 seconds @ 95 























- 23-gauge butterfly catheters 
- 6ml Syringes 
- 1ml and 3ml syringes 
- 2 x 2ml EDTA blood tubes (Purple top, for plasma), labelled 
- 1 x Serum Separator Tube (Yellow tube, for serum), labelled 
- 1.5ml Eppendorf tubes, labelled 
 
Collection Protocol 
1. Try jugular venipuncture first, then medial saphenous venipuncture if necessary 
2. Swab area with alcohol, and shave area if better visualisation is required 
3. For Jugular Venipuncture 
a. Insert butterfly catheter, and draw 5-6mls of blood with a 6ml syringe 
4. For Medial Saphenous venipuncture (restrain cat in lateral recumbency) 
a. Insert butterfly catheter, and using multiple 1 or 3ml syringes, draw 1-2mls of 
blood at a time to prevent clotting within the syringe 
5. Immediately transfer 2mls of whole blood into each EDTA tube 
6. Transfer remaining 1-2mls of blood, and whatever is left in the butterfly catheter into the 
serum separator tube 
7. For diabetic cats only 
a. Use a drop of blood to measure blood glucose and blood ketones using a handheld 
glucometer and ketometer 
8. Transfer plasma and serum to the fridge within 10 minutes of collection 
9. Centrifuge/ separate plasma and serum within 30 minutes of collection 
 
Plasma/ Serum Preparation Protocol 
1. Make a blood smear with the EDTA whole blood 
a. Dry smear and stain with diff-quik solution 
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b. Diff-Quik method 
i. Using a pipette, flood the slide with fixative and leave for 30 seconds, then 
shake off the excess 
ii. Flood slide with diff-quik stain 1, leave for 30 seconds, shake off excess 
iii. Flood slide with diff-quik stain 2, leave for 30 seconds, shake off excess 
iv. Allow to air dry, then place a cover slip on the slide using mounting media 
1. Do this step in the fume hood 
c. Blood smear is used to perform a manual Complete Blood Count 
2. Fill 2 capillary tubes ¾ full with whole blood 
a. Spin capillary tubes in a micro-hematocrit centrifuge for 5 minutes 
b. Read PCV 
c. Break capillary tubes, and empty plasma onto a refractometer, and measure Total 
Protein 
3. Spin plasma and serum in the low speed centrifuge for 7 minutes @ 1800rpm 
a. Pipette separated plasma and serum into labelled Eppendorf tubes 
b. Transfer to the -80 freezer and place in labelled freezer boxes 
i. Plasma stored for eventual use with nesfatin-1 assay 












- 6ml syringe 
- 1 ½ inch x 25G needle 
- Alcohol 




- Lay cat in dorsal recumbency, restrain front legs and hind legs 
- Wet caudal abdomen with alcohol 
- Find bladder with ultrasound probe, and insert needle attached to syringe into the bladder 
using ultrasound guidance 
- Collect approximately 3mls of urine, and place into urine collection tube 
- Keep urine at room temperature, or store in the fridge is urinalysis will be delayed by 
more than 30 minutes 
 
Urine Analysis Protocol 
- Measure urine specific gravity using a refractometer 
- Dip a urine dipstick into the urine before centrifugation and record the results 
- If abnormalities are present on the dipstick (eg proteinuria, hematuria), then analyse urine 
sediment 
- For sediment analysis 
o Centrifuge urine for 3 minutes @ 1800rpm 
o Discard supernatant 
o Place one drop of sediment on a slide and place cover slip over the top 
 Assess urine for cellular elements, bacteria, crystals etc. 
Hematology/ Blood Smear Interpretation Protocol  
At 10 x Objective 
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- Look for any significant platelet clumps at the feathered edge 
- Leukocyte Count:  
o Count leukocytes in the monolayer 
o Average count in 5 fields, divide average by 4 (Leuks x 109/L) 
 
100 x Objective 
- Evaluate RBC morphology 
o Size, shape, colour, inclusions, arrangement/ rouleaux etc 
o E.g. spherocytes, ghosts, Heinz bodies, eccentro, kerato, echino, schizo, acantho 
o Polychromasia, macrocytes, microcytes 
o Nucleated reds  
 
- 100 leukocyte differential count 
o Multiply the percentages of different leukocytes by the total leukocyte count, to 
get the total number of each leukocyte 
o Note any significant changes in leukocyte morphology 
 
- Estimate Platelet Numbers 
o Count platelet numbers in at least 5 fields and average 
 Multiply by 20 x 109/L 
o >10/ 100x field usually means adequate numbers 





FreeStyle Libre® Blood Glucose Monitoring Device 
Standard Operating Procedure For Use In Feline Diabetics 
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Materials Needed 
- Clippers and alcohol 
- Freestyle Libre® Reader 
- Freestyle Libre® Sensor 
- Tissue Glue 
- Tegaderm® Adhesive bandage 
- Soft esophageal collar 
 
1. Shave an area approximately 8cm x 8cm over the dorso-lateral neck 
2. Clean area thoroughly with alcohol, and allow to dry 
3. Apply Tissue glue around the perimeter of the sensor for additional attachment strength 
4. Insert the lancet of the sensor through the skin using the provided applicator and hold 
applicator down for 10 seconds. This allows the adhesive to properly attach the sensor to 
the skin. 
5. Cover the sensor Tegaderm® adhesive bandage for additional protection 
6. Fit the cat with a soft collar (oesophagostomy collar or similar) to prevent help self-
removal of the sensor 
7. Hold the electronic reader against the device and select ‘start new sensor’. This ensures 
that the reader will start to read results from the sensor on the cat. Wait for 1 hour as the 
reader warms up. 
8. Take a glucose measurement 1 hour after the reader has been linked to the sensor, to 
ensure that the sensor is operational 
9. Clients will be instructed to scan the sensor with the reader at least every 8 hours, though 
preferably at least 4-5 times per day. 
10. Sensor and reader will be returned to the clinic once it is no longer attached. Data will be 
collected and saved from this period of time 
